losartan has been researched along with Myocardial Infarction in 218 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ramipril and losartan exert a similar effect upon markers of heart failure and endogenous fibrinolysis, and, with DAPT, a more efficient antiplatelet effect in long term than DAPT alone." | 9.22 | Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial. ( Marinšek, M; Sinkovič, A, 2016) |
| "We examined risks of cardiovascular death, all-cause death, and stroke following MI or coronary revascularization in hypertensive patients with left ventricular hypertrophy (LVH) enrolled in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)." | 9.14 | Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study. ( Cicala, S; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Kjeldsen, SE; Lindholm, LH, 2010) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 9.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| " In Study 2, 44 patients with acute myocardial infarction who randomly received an initial lower dose of either valsartan or losartan after stenting were evaluated." | 9.12 | Do valsartan and losartan have the same effects in the treatment of coronary artery disease? ( Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B, 2007) |
| "Angiotensin-converting enzyme inhibitors have been shown to attenuate adverse remodeling after acute myocardial infarction (AMI), and the same has been suggested for angiotensin II type 1 receptor antagonists in animal models." | 9.11 | Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. ( Andersen, GS; Dahlström, U; Egstrup, K; Gøtzsche, O; Lahiri, A; Møller, JE; Skagen, K, 2004) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 9.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 9.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "Since we saw a non-significant difference in total mortality in favour of captopril, ACE inhibitors should remain first-choice treatment in patients after complicated acute myocardial infarction." | 9.10 | Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. ( Dickstein, K; Kjekshus, J, 2002) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "This study, although underpowered, suggests that neither enalapril nor losartan was superior as compared with each other for left ventricular remodeling after myocardial infarction; however, powerful evidence of equivalence was not provided." | 9.10 | Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction. ( Baggi, JM; Brandi, JM; Cordeiro, JA; de Godoy, MF; Joaquim, MR; Maia, LN; Nicolau, JC; Santos, M; Vítola, JV, 2003) |
| "To verify the efficacy of the combination of captopril (75 mg day) and losartan (25 mg/day) in early postinfarction phases of reperfused anterior acute myocardial infarction." | 9.09 | Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study. ( Bucca, V; Cannizzaro, S; Di Pasquale, P; Giubilato, A; Paterna, S; Scalzo, S, 1999) |
| "We randomized 201 patients with acute myocardial infarction treated with either direct angioplasty, thrombolysis, or heparin alone to the ACE inhibitor captopril or the ATII antagonist losartan." | 9.09 | A comparison of intervention with losartan or captopril in acute myocardial infarction. ( Fischerova, B; Pluhacek, L; Spinar, J; Spinarova, L; Toman, J; Vitovec, J, 2000) |
| "To compare the first dose responses to low dose captopril and losartan in patients with acute myocardial infarction." | 9.09 | First dose hypotension after angiotensin converting enzyme inhibitor captopril and angiotensin II blocker losartan in patients with acute myocardial infarction. ( Fischerova, B; Pluhacek, L; Spinar, J; Spinarova, L; Toman, J; Vitovec, J, 2000) |
| "The OPTIMAAL study was a multicenter, double-blind, randomized, parallel, trial in high-risk patients who were treated early after acute myocardial infarction that compared treatment with an angiotensin-converting enzyme inhibitor (captopril) and a selective angiotensin II antagonist (losartan) on survival and morbidity." | 9.09 | Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiote ( Dickstein, K; Kjekshus, J, 2001) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 8.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "This is the third part in a series of papers dealing with various aspects of clinical pharmacology of the first AT(1)-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Blocker of angiotensin-1 receptor antagonist losartan. Part III. Experience in therapy for chronic heart failure and after acute myocardial infarction]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| " We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension." | 8.31 | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients. ( Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG, 2023) |
| "To study the pro-apoptotic effect of Losartan on myocardial cells after acute myocardial infarction (AMI) in rats." | 7.96 | Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway. ( Liu, R; Xin, LH; Yang, XW, 2020) |
| "Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)." | 7.91 | Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019) |
| "Subcutaneous injection of isoproterenol (85 mg/kg) on last 2 consecutive days in per se group and 7 days treatment of different groups at 24 h interval induced myocardial infarction in Wistar rats." | 7.83 | Histamine H3 Receptor Agonist Imetit Attenuated Isoproterenol Induced Renin Angiotensin System and Sympathetic Nervous System Overactivity in Myocardial Infarction of Rats. ( Akhtar, M; Hass, C; Khanam, R; Najmi, AK; Panda, BP, 2016) |
| "Modulation of vagal tone using electrical vagal nerve stimulation or pharmacological acetylcholinesterase inhibition by donepezil exerts beneficial effects in an animal model of chronic heart failure (CHF)." | 7.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| "This study tested the reversal of subcellular remodelling in heart failure due to myocardial infarction (MI) upon treatment with losartan, an angiotensin II receptor antagonist." | 7.78 | Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. ( Babick, A; Chapman, D; Dhalla, NS; Elimban, V; Zieroth, S, 2012) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 7.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "This is a retrospective analysis of a subgroup of the OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) trial in which serum Epo levels were measured at baseline, at 1 month, and at 1 and 2 years in 224 patients with an acute myocardial infarction complicated by signs or symptoms of heart failure." | 7.75 | Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. ( Anker, SD; Belonje, AM; Dickstein, K; Ponikowski, P; van Veldhuisen, DJ; von Haehling, S; Voors, AA; Westenbrink, BD, 2009) |
| "Losartan may reduce reactive fibrosis not only by attenuating the Ald signaling pathway but also by decreasing the expression of MR." | 7.74 | [Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. ( Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008) |
| "This study tests the hypothesis that peroxisome proliferator activated receptor-gamma coactivator 1alpha (PGC-1alpha) and the integrity of gap junctions (GJs) were suppressed and the number of apoptotic bodies was increased in remote viable areas of left ventricle following acute myocardial infarction (AMI), which can be reversed by losartan therapy." | 7.74 | Losartan preserves integrity of cardiac gap junctions and PGC-1 alpha gene expression and prevents cellular apoptosis in remote area of left ventricular myocardium following acute myocardial infarction. ( Chang, LT; Chua, S; Sheu, JJ; Sun, CK; Wang, CY; Wu, CJ; Yip, HK; Youssef, AA, 2007) |
| "The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study was performed to investigate the relationship between blood pressure (BP) and development of stroke or myocardial infarction (MI) in Japanese hypertensive patients." | 7.74 | Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. ( Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2008) |
| " We employed rats with myocardial infarction (MI) to examine effects of an angiotensin-converting enzyme inhibitor, imidapril, on SR Ca(2+) transport, protein content, and gene expression." | 7.73 | Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment. ( Dhalla, NS; Netticadan, T; Ren, B; Saini, HK; Shao, Q; Takeda, N, 2005) |
| " The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)." | 7.73 | Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005) |
| "To compare the effects of matrix metalloproteinase (MMP) inhibitor doxycycline, losartan, and their combination on the expression of MMP-8, 13, tissue inhibitor of MMP-1, 2 (TIMP-1, 2), and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction (AMI) in rats." | 7.73 | [Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats]. ( Chen, X; Chen, ZJ; Ruan, YM; Tian, Y; Yang, YJ; Zhang, P; Zhou, YW, 2005) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 7.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol." | 7.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| "It has been verified that losartan has beneficial effects on ventricular remodeling (VRM) after acute myocardial infarction (AMI), but the effects of carvedilol alone or in combination with losartan on this condition have not been defined." | 7.72 | Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. ( Chen, JL; Chen, ZJ; Gao, RL; Ruan, YM; Tang, YD; Wang, PH; Yang, YJ; Zhang, P; Zhou, YW, 2003) |
| " Because aldosterone production in the heart increases after myocardial infarction (MI), we investigated the effect of chronic administration of spironolactone, an aldosterone receptor antagonist, in rats after MI compared with the effects produced by losartan and hydralazine." | 7.72 | Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. ( de Resende, MM; Gomes, Mda G; Leite, CM; Milanez, Mda C; Mill, JG, 2003) |
| "We investigated in Lewis normotensive rats the effect of coronary artery ligation on the expression of cardiac angiotensin-converting enzymes (ACE and ACE 2) and angiotensin II type-1 receptors (AT1a-R) 28 days after myocardial infarction." | 7.72 | Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. ( Averill, DB; Brosnihan, KB; Ferrario, CM; Gallagher, PE; Ishiyama, Y; Tallant, EA, 2004) |
| "This study was carried out to investigate the effects of early administration of losartan on ventricular remodelling (VR) in rabbits with experimental myocardial infarction (MI)." | 7.72 | [Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. ( Depetris Chauvin, A; Gelpi, RJ; González, GE; Mangas, F; Morales, C; Palleiro, J; Rodríguez, M, 2004) |
| "The effects of enalapril, an angiotensin converting enzyme (ACE) inhibitor, and losartan, an angiotensin II receptor type I antagonist, were investigated on alterations in myofibrillar ATPase activity as well as myosin heavy chain (MHC) content and gene expression in failing hearts following myocardial infarction (MI)." | 7.72 | Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. ( Dhalla, NS; Guo, X; Wang, J, 2004) |
| "To compare the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in the rat." | 7.71 | Comparison of the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling after acute myocardial infarction in the rat. ( Laifeng, S; Pei, Z; Xinglin, X; Yanwen, Z; Yi, T; Yingmao, R; Yishu, X; Yongli, L; Yuejin, Y; Zaijia, C, 2002) |
| "To compare the effects of carvedilol, losartan and their combination in preventing from left ventricular remodeling (LVRM) after acute myocardial infarction(AMI) in rats." | 7.71 | [Comparative effects of carvedilol, losartan and their combination in preventing left ventricular remodeling after acute myocardial infarction in rats]. ( Chen, Z; Gao, R; Li, Y; Ruan, Y; Tang, Y; Yang, Y, 2001) |
| "We studied the effects of chronic losartan (Los) treatment on contractile function of isolated right ventricular (RV) trabeculae from rat hearts 12 wk after left ventricular (LV) myocardial infarction (MI) had been induced by ligation of the left anterior descending artery at 4 wk of age." | 7.71 | Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction. ( Daniëls, MC; de Tombe, PP; Keller, RS, 2001) |
| "The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure." | 7.71 | Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. ( Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002) |
| "EXP3174, but not losartan nor captopril, reduced the incidence of lethal ischemic ventricular arrhythmia in this preparation." | 7.70 | EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. ( Gould, RJ; Grossman, W; Kusma, SE; Lynch, JJ; Painter, CA; Stump, GL; Thomas, JM; Wallace, AA, 1999) |
| "To determine the effects of losartan and captopril treatment on ventricular remodeling and function after myocardial infarction in rats." | 7.70 | Comparative effects of losartan and captopril on ventricular remodeling and function after myocardial infarction in the rat. ( Chen, H; Pan, W; Pu, S; Shen, X; Yang, Y; Zhang, G, 1998) |
| "We investigated the haemodynamic parameters and the regulation of cardiac mRNA levels of the angiotensin receptor subtypes, AT1 and AT2, by the AT,-receptor antagonist losartan in rat heart during the acute phase of myocardial infarction." | 7.70 | Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction. ( Li, J; Schäfer, H; Schmidt, W; Unger, T; Yao, T; Zhu, YC; Zhu, YZ, 2000) |
| "To determine whether cardioprotection after chronic angiotensin II (Ang II) type 1 (AT(1)) receptor blockade involves Ang II type 2 (AT(2)) receptor expression and protein kinase C-epsilon (PKC(epsilon)) activation, we measured in vivo haemodynamics and left ventricular (LV) remodelling and dysfunction (echocardiogram/ Doppler) and ex vivo AT(1)/AT(2)-receptor expression, IP(3)R (1, 4, 5-inositol trisphosphate type 2 receptor) and PKC(epsilon) proteins in dogs with acutely reperfused (90 minutes ischaemia, 90 minutes reperfusion) myocardial infarction (MI) following seven days of AT(1)-receptor blockade with oral losartan or UP269-6." | 7.70 | Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-recep ( Jugdutt, BI; Menon, V; Xu, Y, 2000) |
| "We compared the effects pretreatment with the ACE inhibitor moexipril with those of the type 1 angiotensin (AT1)-receptor antagonist losartan on structural and functional cardiac parameters after myocardial infarction in rats." | 7.69 | Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. ( Adamiak, D; Kregel, KC; Mott, A; Redlich, T; Stauss, HM; Unger, T; Zhu, YC, 1994) |
| "There was (1) low angiotensin receptor binding in normal myocardium; (2) markedly increased angiotensin II receptor binding at the site of left ventricular myocardial infarction and endocardial fibrosis of the interventricular septum at day 3 and weeks 1, 2, 4, and 8; (3) high angiotensin II receptor binding in the pericardial fibrosis that followed pericardiotomy, and in the fibrosis that appeared in response to suture insertion around the left coronary artery, in both infarcted and sham operated rats; (4) total displacement of normal and connective tissue angiotensin II receptor binding by DuP753, but not by PD123177; (5) ACE inhibition by lisinopril, but no change in angiotensin II receptor binding, at all sites of fibrosis; and (6) significant attenuation by lisinopril of collagen formation in the visceral pericardium of sham operated controls." | 7.69 | Angiotensin II receptor binding following myocardial infarction in the rat. ( Sun, Y; Weber, KT, 1994) |
| " These results suggest that inhibition of generation of angiotensin II and AT1 receptor blockade are equally effective in preventing important features of ventricular remodeling after myocardial infarction." | 7.69 | Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. ( Drexler, H; Holtz, J; Meybrunn, M; Riede, UN; Schieffer, B; Seitz, S; Wirger, A, 1994) |
| "Rats with a moderate to large myocardial infarction were treated with captopril (2 g/liter drinking water, n = 87) or losartan (2 g/liter drinking water, n = 96)." | 7.69 | Survival after myocardial infarction in rats: captopril versus losartan. ( Goldman, S; Johnson, CS; Milavetz, JJ; Morkin, E; Raya, TE, 1996) |
| "We wished to determine whether enhanced bioavailability of bradykinin (BK) and vasodilatory prostaglandins contribute to renovascular and sodium-handling effects of angiotensin-converting enzyme (ACE) inhibition after myocardial infarction (MI)." | 7.69 | Relative contribution of angiotensin II, bradykinin, and prostaglandins to the renal effects of converting enzyme inhibition in rats after chronic myocardial infarction. ( Deck, CC; Gaballa, MA; Raya, TE, 1996) |
| "To assess the efficacy of losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl)methyl]imidazole, potassium salt), an angiotensin II receptor antagonist, on acute myocardial ischemia, 36 four-month-old spontaneously hypertensive rats were used." | 7.69 | Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats. ( Ding, YA; Lee, YM; Peng, YY; Yen, MH, 1997) |
| "To study the effects of losartan (Los) and captopril (Cap) treatment on expression of cardiac angiotensin II (Ang) AT1 receptor mRNA in rats following myocardial infarction (MI)." | 7.69 | Effect of losartan and captopril on expression of cardiac angiotensin II AT1 receptor mRNA in rats following myocardial infarction. ( Chen, HZ; Peng, TQ; Pu, SY; Shen, XD; Yang, YZ; Zhang, GX, 1997) |
| "We examined the effect of losartan on ventricular remodeling after AMI comparatively with that of enalapril." | 6.71 | Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction. ( Hanada, H; Higuma, T; Ishizaka, H; Maeda, N; Matsunaga, T; Mori, Y; Okumura, K; Onodera, H; Osanai, T; Sasaki, S; Tamura, Y; Yoshimachi, F, 2005) |
| "Metoprolol treatment for 2 weeks improved LV systolic function." | 5.35 | Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. ( Kerkelä, R; Kubin, AM; Leskinen, H; Pieviläinen, O; Ruskoaho, H; Serpi, R; Soini, Y; Tenhunen, O; Tolonen, AM; Vaskivuo, T, 2009) |
| "ASA, captopril or losartan were given at a concentration of 40 mg/kg/day in drinking water." | 5.32 | Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function. ( Browne, AE; Chatterjee, K; Grossman, W; Karliner, JS; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2003) |
| "Losartan treatment after myocardial infarction reduced the incidence of cMI from 30." | 5.32 | Losartan inhibits myosin isoform shift after myocardial infarction in rats. ( Davidoff, AW; Elkassem, S; Saito, K; ter Keurs, HE; Zhang, ML, 2003) |
| " Losartan (15 mg/kg/day) resulted in a rightward shift of the AII pressor dose-response curve by a factor of 32-40." | 5.28 | Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. ( Cleutjens, JP; Daemen, MJ; Schoemaker, RG; Smits, JF; van Krimpen, C, 1992) |
| "Ramipril and losartan exert a similar effect upon markers of heart failure and endogenous fibrinolysis, and, with DAPT, a more efficient antiplatelet effect in long term than DAPT alone." | 5.22 | Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial. ( Marinšek, M; Sinkovič, A, 2016) |
| "Carotid endarterectomy and medical therapy (aspirin) were shown superior to medical therapy alone for asymptomatic (≥ 60%) carotid stenosis." | 5.20 | Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study. ( Boytsov, S; Deev, A; Dupik, N; Kolos, I; Loukianov, M, 2015) |
| " atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)." | 5.20 | Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015) |
| "8 years' losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke." | 5.20 | Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. ( Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2015) |
| "8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.17 | Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. ( Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Lund, BP; Nieminen, MS; Okin, PM; Wachtell, K, 2013) |
| "8 years of randomized losartan-based or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.15 | In-treatment stroke volume predicts cardiovascular risk in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Lønnebakken, MT; Wachtell, K, 2011) |
| "A total of 937 hypertensive patients with ECG LVH were studied by echocardiography in the Losartan Intervention For Endpoint reduction in hypertension study." | 5.14 | Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Olofsson, M; Papademetriou, V; Wachtell, K, 2009) |
| "We examined risks of cardiovascular death, all-cause death, and stroke following MI or coronary revascularization in hypertensive patients with left ventricular hypertrophy (LVH) enrolled in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)." | 5.14 | Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study. ( Cicala, S; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Kjeldsen, SE; Lindholm, LH, 2010) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 5.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| " We also studied whether long-term treatment with isosorbide-5-mononitrate (IS-5-MN) in combination with standard HF therapy affects P-MDA levels in patients with evidence of left ventricular (LV) dysfunction following acute myocardial infarction (AMI)." | 5.12 | Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy. ( Gottsäter, A; Ohlin, AK; Ohlin, H; Tingberg, E, 2006) |
| " In Study 2, 44 patients with acute myocardial infarction who randomly received an initial lower dose of either valsartan or losartan after stenting were evaluated." | 5.12 | Do valsartan and losartan have the same effects in the treatment of coronary artery disease? ( Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B, 2007) |
| "Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.12 | The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. ( Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA, 2007) |
| "Because no controlled clinical studies are available about the possible role of angiotensin II receptor blockers in preventing effort myocardial ischemia, we evaluated the effect of angiotensin II receptor blocker/losartan in preventing exercise-induced myocardial ischemia in patients with coronary artery disease." | 5.12 | Effect of losartan in treatment of exercise-induced myocardial ischemia. ( Abete, P; Cacciatore, F; Corbi, G; Ferrara, N; Furgi, G; Longobardi, G; Rengo, F; Vitale, DF, 2007) |
| "Angiotensin-converting enzyme inhibitors have been shown to attenuate adverse remodeling after acute myocardial infarction (AMI), and the same has been suggested for angiotensin II type 1 receptor antagonists in animal models." | 5.11 | Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. ( Andersen, GS; Dahlström, U; Egstrup, K; Gøtzsche, O; Lahiri, A; Møller, JE; Skagen, K, 2004) |
| "The Losartan Intervention For End point reduction in hypertension (LIFE) study showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke, and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria." | 5.11 | Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, S; Zhang, Z, 2004) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 5.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal-protective effects." | 5.11 | Losartan and end-organ protection--lessons from the RENAAL study. ( Brenner, BM; Dickson, TZ; Kowey, PR; Shahinfar, S; Zhang, Z, 2005) |
| "The OPTIMAAL trial randomized 5477 patients with heart failure or evidence of left ventricular dysfunction following acute MI to losartan or captopril." | 5.11 | Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. ( Cleland, JG; Dickstein, K; Kjekshus, J; Orn, S; Romo, M, 2005) |
| "Since we saw a non-significant difference in total mortality in favour of captopril, ACE inhibitors should remain first-choice treatment in patients after complicated acute myocardial infarction." | 5.10 | Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. ( Dickstein, K; Kjekshus, J, 2002) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) is the first major study to compare an angiotensin II Type 1 antagonist losartan (Cozaar trade mark, Merck) with an ACE inhibitor captonpril (Capoten trade mark, Elan) after myocardial infarction in patients with left ventricular dysfunction." | 5.10 | ACE inhibitors or AT-1 antagonists - which is OPTIMAAL after acute myocardial infarction? ( Doggrell, SA, 2003) |
| "This study, although underpowered, suggests that neither enalapril nor losartan was superior as compared with each other for left ventricular remodeling after myocardial infarction; however, powerful evidence of equivalence was not provided." | 5.10 | Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction. ( Baggi, JM; Brandi, JM; Cordeiro, JA; de Godoy, MF; Joaquim, MR; Maia, LN; Nicolau, JC; Santos, M; Vítola, JV, 2003) |
| "To verify the efficacy of the combination of captopril (75 mg day) and losartan (25 mg/day) in early postinfarction phases of reperfused anterior acute myocardial infarction." | 5.09 | Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study. ( Bucca, V; Cannizzaro, S; Di Pasquale, P; Giubilato, A; Paterna, S; Scalzo, S, 1999) |
| "We randomized 201 patients with acute myocardial infarction treated with either direct angioplasty, thrombolysis, or heparin alone to the ACE inhibitor captopril or the ATII antagonist losartan." | 5.09 | A comparison of intervention with losartan or captopril in acute myocardial infarction. ( Fischerova, B; Pluhacek, L; Spinar, J; Spinarova, L; Toman, J; Vitovec, J, 2000) |
| "To compare the first dose responses to low dose captopril and losartan in patients with acute myocardial infarction." | 5.09 | First dose hypotension after angiotensin converting enzyme inhibitor captopril and angiotensin II blocker losartan in patients with acute myocardial infarction. ( Fischerova, B; Pluhacek, L; Spinar, J; Spinarova, L; Toman, J; Vitovec, J, 2000) |
| "The OPTIMAAL study was a multicenter, double-blind, randomized, parallel, trial in high-risk patients who were treated early after acute myocardial infarction that compared treatment with an angiotensin-converting enzyme inhibitor (captopril) and a selective angiotensin II antagonist (losartan) on survival and morbidity." | 5.09 | Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiote ( Dickstein, K; Kjekshus, J, 2001) |
| " This study has attempted to verify the feasibility, safety and tolerability of a combined treatment using captopril (75 mg/day) and losartan (25 mg/day), and to ascertain its ability to reduce the formation and action of A II in the early post-infarction phase of reperfused anterior myocardial infarction (AMI)." | 5.08 | Captopril plus losartan in early post-infarction. Neurohormonal effects: a pilot study. ( Cannizzaro, S; Di Pasquale, P; Iachininoto, R; Longo, AM; Maringhini, G; Paterna, S, 1997) |
| " Thus, the observed outcomes benefits favoring losartan may involve other possible mechanisms, including differential effects of losartan and atenolol on LVH regression, left atrial diameter, atrial fibrillation, brain natriuretic peptide, vascular structure, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new-onset diabetes, and lipid metabolism." | 4.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| " The LIFE study concluded that losartan is superior compared to atenolol in terms of prevention of cardiovascular morbidity and mortality, the benefit being for CVA without changing the incidence of myocardial infarction." | 4.82 | [The best of clinical pharmacology in 2002]. ( Ambrosi, P; Andréjak, M; Gayet, JL, 2003) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| "This is the third part in a series of papers dealing with various aspects of clinical pharmacology of the first AT(1)-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Blocker of angiotensin-1 receptor antagonist losartan. Part III. Experience in therapy for chronic heart failure and after acute myocardial infarction]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| " We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension." | 4.31 | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients. ( Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG, 2023) |
| "To study the pro-apoptotic effect of Losartan on myocardial cells after acute myocardial infarction (AMI) in rats." | 3.96 | Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway. ( Liu, R; Xin, LH; Yang, XW, 2020) |
| "Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI)." | 3.91 | Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. ( Ahmad, M; Leenen, FHH; Llorens-Cortes, C; Marc, Y, 2019) |
| "Subcutaneous injection of isoproterenol (85 mg/kg) on last 2 consecutive days in per se group and 7 days treatment of different groups at 24 h interval induced myocardial infarction in Wistar rats." | 3.83 | Histamine H3 Receptor Agonist Imetit Attenuated Isoproterenol Induced Renin Angiotensin System and Sympathetic Nervous System Overactivity in Myocardial Infarction of Rats. ( Akhtar, M; Hass, C; Khanam, R; Najmi, AK; Panda, BP, 2016) |
| "Modulation of vagal tone using electrical vagal nerve stimulation or pharmacological acetylcholinesterase inhibition by donepezil exerts beneficial effects in an animal model of chronic heart failure (CHF)." | 3.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| "Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension." | 3.79 | Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2013) |
| " In this study, we investigated the cardioprotective effects of combination therapy with low-dose simvastatin and low-dose losartan using a rat myocardial infarction model." | 3.78 | Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model. ( Abe, S; Arikawa, T; Asanuma, H; Hikichi, Y; Inoue, T; Kikuchi, M; Kitakaze, M; Node, K; Sanada, S; Sohma, R; Taguchi, I; Toyoda, S, 2012) |
| "This study tested the reversal of subcellular remodelling in heart failure due to myocardial infarction (MI) upon treatment with losartan, an angiotensin II receptor antagonist." | 3.78 | Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. ( Babick, A; Chapman, D; Dhalla, NS; Elimban, V; Zieroth, S, 2012) |
| "The activation of angiotensin II type 1 receptor (AT1R) in the brain plays a pivotal role in enhanced sympathetic drive in heart failure (HF)." | 3.77 | Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure. ( Hirooka, Y; Kishi, T; Ogawa, K; Sunagawa, K, 2011) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 3.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "This is a retrospective analysis of a subgroup of the OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) trial in which serum Epo levels were measured at baseline, at 1 month, and at 1 and 2 years in 224 patients with an acute myocardial infarction complicated by signs or symptoms of heart failure." | 3.75 | Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. ( Anker, SD; Belonje, AM; Dickstein, K; Ponikowski, P; van Veldhuisen, DJ; von Haehling, S; Voors, AA; Westenbrink, BD, 2009) |
| "We tested hypothesis that acute myocardial infarction (AMI) induces cellular apoptosis and serial changes of protein kinase C epsilon (PKC-epsilon) and p38 mitogen-activated protein kinase (p38 MAPK), and tested cardio-protective effect of losartan in this condition." | 3.75 | Time courses of subcellular signal transduction and cellular apoptosis in remote viable myocardium of rat left ventricles following acute myocardial infarction: role of pharmacomodulation. ( Chang, LT; Chua, S; Lee, FY; Sheu, JJ; Sun, CK; Wu, CJ; Yang, CH; Yip, HK; Youssef, AA, 2009) |
| "Losartan may reduce reactive fibrosis not only by attenuating the Ald signaling pathway but also by decreasing the expression of MR." | 3.74 | [Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. ( Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008) |
| "The purpose of this study was to evaluate the feasibility of noninvasive imaging of angiotensin II (AT) receptor upregulation in a mouse model of post-myocardial infarction (MI) heart failure (HF)." | 3.74 | Noninvasive imaging of angiotensin receptors after myocardial infarction. ( Bjurgert, E; Cuthbertson, A; Hofstra, L; Indrevoll, B; Kindberg, GM; Krasieva, TB; Lovhaug, D; Narula, J; Narula, N; Petersen, LB; Petrov, AD; Reutelingsperger, CP; Solbakken, M; Tromberg, BJ; Vannan, MA; Verjans, JW, 2008) |
| "This study tests the hypothesis that peroxisome proliferator activated receptor-gamma coactivator 1alpha (PGC-1alpha) and the integrity of gap junctions (GJs) were suppressed and the number of apoptotic bodies was increased in remote viable areas of left ventricle following acute myocardial infarction (AMI), which can be reversed by losartan therapy." | 3.74 | Losartan preserves integrity of cardiac gap junctions and PGC-1 alpha gene expression and prevents cellular apoptosis in remote area of left ventricular myocardium following acute myocardial infarction. ( Chang, LT; Chua, S; Sheu, JJ; Sun, CK; Wang, CY; Wu, CJ; Yip, HK; Youssef, AA, 2007) |
| "The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study was performed to investigate the relationship between blood pressure (BP) and development of stroke or myocardial infarction (MI) in Japanese hypertensive patients." | 3.74 | Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. ( Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2008) |
| " We employed rats with myocardial infarction (MI) to examine effects of an angiotensin-converting enzyme inhibitor, imidapril, on SR Ca(2+) transport, protein content, and gene expression." | 3.73 | Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment. ( Dhalla, NS; Netticadan, T; Ren, B; Saini, HK; Shao, Q; Takeda, N, 2005) |
| " The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)." | 3.73 | Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005) |
| "To compare the effects of matrix metalloproteinase (MMP) inhibitor doxycycline, losartan, and their combination on the expression of MMP-8, 13, tissue inhibitor of MMP-1, 2 (TIMP-1, 2), and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction (AMI) in rats." | 3.73 | [Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats]. ( Chen, X; Chen, ZJ; Ruan, YM; Tian, Y; Yang, YJ; Zhang, P; Zhou, YW, 2005) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 3.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "To compare the effects of doxycycline, losartan, and their combination in the prevention of left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in rats." | 3.73 | [Comparison of doxycycline, losartan, and their combination in the prevention of post-infarction remodeling in rats]. ( Chen, X; Chen, ZJ; Gao, RL; Ruan, YM; Tian, Y; Yang, YJ; Zhang, P; Zhou, YW, 2005) |
| " (3) Five clinical trials have evaluated angiotensin II receptor antagonists (candesartan, losartan and valsartan) in terms of their effect on mortality and on the risk of clinical deterioration in patients with symptomatic heart failure, but without severe renal failure, hyperkalemia or hypotension." | 3.73 | Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. ( , 2005) |
| "The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study demonstrated a 13% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke or death) for patients with hypertension and electrocardiographically diagnosed left ventricular hypertrophy (LVH) treated with losartan compared with atenolol." | 3.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| "It has been verified that losartan has beneficial effects on ventricular remodeling (VRM) after acute myocardial infarction (AMI), but the effects of carvedilol alone or in combination with losartan on this condition have not been defined." | 3.72 | Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. ( Chen, JL; Chen, ZJ; Gao, RL; Ruan, YM; Tang, YD; Wang, PH; Yang, YJ; Zhang, P; Zhou, YW, 2003) |
| " Because aldosterone production in the heart increases after myocardial infarction (MI), we investigated the effect of chronic administration of spironolactone, an aldosterone receptor antagonist, in rats after MI compared with the effects produced by losartan and hydralazine." | 3.72 | Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. ( de Resende, MM; Gomes, Mda G; Leite, CM; Milanez, Mda C; Mill, JG, 2003) |
| "After myocardial infarction, angiotensin II (AngII) promotes ventricular remodeling and deposition of extracellular matrix (ECM), e." | 3.72 | Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro. ( Chen, WB; Fischer, JW; Kruse, ML; Petrik, C; Stoll, M; Stöter, K; Tiede, K; Ungefroren, H; Unger, T, 2003) |
| "We investigated in Lewis normotensive rats the effect of coronary artery ligation on the expression of cardiac angiotensin-converting enzymes (ACE and ACE 2) and angiotensin II type-1 receptors (AT1a-R) 28 days after myocardial infarction." | 3.72 | Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. ( Averill, DB; Brosnihan, KB; Ferrario, CM; Gallagher, PE; Ishiyama, Y; Tallant, EA, 2004) |
| "This study was carried out to investigate the effects of early administration of losartan on ventricular remodelling (VR) in rabbits with experimental myocardial infarction (MI)." | 3.72 | [Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction]. ( Depetris Chauvin, A; Gelpi, RJ; González, GE; Mangas, F; Morales, C; Palleiro, J; Rodríguez, M, 2004) |
| "The effects of enalapril, an angiotensin converting enzyme (ACE) inhibitor, and losartan, an angiotensin II receptor type I antagonist, were investigated on alterations in myofibrillar ATPase activity as well as myosin heavy chain (MHC) content and gene expression in failing hearts following myocardial infarction (MI)." | 3.72 | Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. ( Dhalla, NS; Guo, X; Wang, J, 2004) |
| "The purpose of this study was to determine if the cardiac sympathetic afferent reflex (CSAR) was augmented in rats with coronary ligation-induced chronic heart failure (CHF), and if central angiotensin II (ANG II) was involved in this enhancement." | 3.71 | Central AT1 receptors are involved in the enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure. ( Wang, W; Zhu, GQ; Zucker, IH, 2002) |
| "To compare the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in the rat." | 3.71 | Comparison of the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling after acute myocardial infarction in the rat. ( Laifeng, S; Pei, Z; Xinglin, X; Yanwen, Z; Yi, T; Yingmao, R; Yishu, X; Yongli, L; Yuejin, Y; Zaijia, C, 2002) |
| "To compare the effects of carvedilol, losartan and their combination in preventing from left ventricular remodeling (LVRM) after acute myocardial infarction(AMI) in rats." | 3.71 | [Comparative effects of carvedilol, losartan and their combination in preventing left ventricular remodeling after acute myocardial infarction in rats]. ( Chen, Z; Gao, R; Li, Y; Ruan, Y; Tang, Y; Yang, Y, 2001) |
| " MASSIVE PROTEINURIA: An angiotensin II inhibitor, losartan, has been found to be effective against massive proteinuria (> 3." | 3.71 | [Complications in kidney transplantation]. ( Ouali, N, 2001) |
| "We studied the effects of chronic losartan (Los) treatment on contractile function of isolated right ventricular (RV) trabeculae from rat hearts 12 wk after left ventricular (LV) myocardial infarction (MI) had been induced by ligation of the left anterior descending artery at 4 wk of age." | 3.71 | Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction. ( Daniëls, MC; de Tombe, PP; Keller, RS, 2001) |
| "A previous study by our group showed that 10 weeks of pretreatment with losartan reduced myocardial infarct size and arrhythmias in a rat model of ischaemia-reperfusion." | 3.71 | Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor. ( Browne, AE; Chatterjee, K; Lee, RJ; Parmley, WW; Sievers, RE; Sun, Y; Zhu, B, 2001) |
| "The purpose of this study was to compare long-term effects of cariporide with those of losartan in postinfarction heart failure." | 3.71 | Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. ( Ellingsen, O; Falck, G; Loennechen, JP; Wisløff, U, 2002) |
| " Losartan increased the threshold for ventricular fibrillation (p=0." | 3.71 | The renin-angiotensin system does not contribute to the endothelial dysfunction and increased infarct size in rats exposed to second hand smoke. ( Browne, AE; Chair, K; Chatterjee, K; Glantz, SA; Hillman, RT; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2002) |
| " At similar blood pressure control, losartan, as compared to atenolol, reduced the relative risk of primary cardiovascular event (death, myocardial infarction, or stroke) by 13% (p = 0." | 3.71 | [Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan]. ( Scheen, AJ, 2002) |
| " Because brain "ouabain" may act by activating the brain renin-angiotensin system (RAS), the aim of the present study was to assess whether chronic treatment with the AT1-receptor blocker losartan given centrally normalizes the sympathetic hyperactivity and impairment of baroreflex function in Wistar rats with CHF postmyocardial infarction (MI)." | 3.70 | Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. ( Huang, BS; Leenen, FH; Zhang, W, 1999) |
| "EXP3174, but not losartan nor captopril, reduced the incidence of lethal ischemic ventricular arrhythmia in this preparation." | 3.70 | EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. ( Gould, RJ; Grossman, W; Kusma, SE; Lynch, JJ; Painter, CA; Stump, GL; Thomas, JM; Wallace, AA, 1999) |
| "To evaluate the effects of losartan on ventricular remodeling and on survival after myocardial infarction in rats." | 3.70 | Effects of losartan on ventricular remodeling in experimental infarction in rats. ( Matsubara, BB; Matsubara, LS; Paiva, SA; Spadaro, J; Zornoff, LA, 2000) |
| "To determine the effects of losartan and captopril treatment on ventricular remodeling and function after myocardial infarction in rats." | 3.70 | Comparative effects of losartan and captopril on ventricular remodeling and function after myocardial infarction in the rat. ( Chen, H; Pan, W; Pu, S; Shen, X; Yang, Y; Zhang, G, 1998) |
| "We investigated the haemodynamic parameters and the regulation of cardiac mRNA levels of the angiotensin receptor subtypes, AT1 and AT2, by the AT,-receptor antagonist losartan in rat heart during the acute phase of myocardial infarction." | 3.70 | Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction. ( Li, J; Schäfer, H; Schmidt, W; Unger, T; Yao, T; Zhu, YC; Zhu, YZ, 2000) |
| "To determine whether cardioprotection after chronic angiotensin II (Ang II) type 1 (AT(1)) receptor blockade involves Ang II type 2 (AT(2)) receptor expression and protein kinase C-epsilon (PKC(epsilon)) activation, we measured in vivo haemodynamics and left ventricular (LV) remodelling and dysfunction (echocardiogram/ Doppler) and ex vivo AT(1)/AT(2)-receptor expression, IP(3)R (1, 4, 5-inositol trisphosphate type 2 receptor) and PKC(epsilon) proteins in dogs with acutely reperfused (90 minutes ischaemia, 90 minutes reperfusion) myocardial infarction (MI) following seven days of AT(1)-receptor blockade with oral losartan or UP269-6." | 3.70 | Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-recep ( Jugdutt, BI; Menon, V; Xu, Y, 2000) |
| "To determine whether cardiac unloading by inhibition of angiotensin I (AI) to AII conversion by captopril or blockade of the AII receptor (AT1) by losartan was more effective in prevention of the detrimental hemodynamic consequences of myocardial infarction (MI), inhibition of metabolic production of AII by captopril was compared with blockade of AT1 with losartan in Sprague-Dawley rats with large MI." | 3.69 | Efficacy of angiotensin-converting enzyme inhibition and AT1 receptor blockade on cardiac pump performance after myocardial infarction in rats. ( Anversa, P; Capasso, JM; Herman, MV; Li, P; Meggs, LG, 1994) |
| "We compared the effects pretreatment with the ACE inhibitor moexipril with those of the type 1 angiotensin (AT1)-receptor antagonist losartan on structural and functional cardiac parameters after myocardial infarction in rats." | 3.69 | Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. ( Adamiak, D; Kregel, KC; Mott, A; Redlich, T; Stauss, HM; Unger, T; Zhu, YC, 1994) |
| "There was (1) low angiotensin receptor binding in normal myocardium; (2) markedly increased angiotensin II receptor binding at the site of left ventricular myocardial infarction and endocardial fibrosis of the interventricular septum at day 3 and weeks 1, 2, 4, and 8; (3) high angiotensin II receptor binding in the pericardial fibrosis that followed pericardiotomy, and in the fibrosis that appeared in response to suture insertion around the left coronary artery, in both infarcted and sham operated rats; (4) total displacement of normal and connective tissue angiotensin II receptor binding by DuP753, but not by PD123177; (5) ACE inhibition by lisinopril, but no change in angiotensin II receptor binding, at all sites of fibrosis; and (6) significant attenuation by lisinopril of collagen formation in the visceral pericardium of sham operated controls." | 3.69 | Angiotensin II receptor binding following myocardial infarction in the rat. ( Sun, Y; Weber, KT, 1994) |
| " These results suggest that inhibition of generation of angiotensin II and AT1 receptor blockade are equally effective in preventing important features of ventricular remodeling after myocardial infarction." | 3.69 | Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. ( Drexler, H; Holtz, J; Meybrunn, M; Riede, UN; Schieffer, B; Seitz, S; Wirger, A, 1994) |
| "Rats with a moderate to large myocardial infarction were treated with captopril (2 g/liter drinking water, n = 87) or losartan (2 g/liter drinking water, n = 96)." | 3.69 | Survival after myocardial infarction in rats: captopril versus losartan. ( Goldman, S; Johnson, CS; Milavetz, JJ; Morkin, E; Raya, TE, 1996) |
| "We wished to determine whether enhanced bioavailability of bradykinin (BK) and vasodilatory prostaglandins contribute to renovascular and sodium-handling effects of angiotensin-converting enzyme (ACE) inhibition after myocardial infarction (MI)." | 3.69 | Relative contribution of angiotensin II, bradykinin, and prostaglandins to the renal effects of converting enzyme inhibition in rats after chronic myocardial infarction. ( Deck, CC; Gaballa, MA; Raya, TE, 1996) |
| "To assess the efficacy of losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl)methyl]imidazole, potassium salt), an angiotensin II receptor antagonist, on acute myocardial ischemia, 36 four-month-old spontaneously hypertensive rats were used." | 3.69 | Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats. ( Ding, YA; Lee, YM; Peng, YY; Yen, MH, 1997) |
| "To study the effects of losartan (Los) and captopril (Cap) treatment on expression of cardiac angiotensin II (Ang) AT1 receptor mRNA in rats following myocardial infarction (MI)." | 3.69 | Effect of losartan and captopril on expression of cardiac angiotensin II AT1 receptor mRNA in rats following myocardial infarction. ( Chen, HZ; Peng, TQ; Pu, SY; Shen, XD; Yang, YZ; Zhang, GX, 1997) |
| "The reduction in the number of ESRD days over 4 years in patients treated with losartan significantly decreased costs associated with ESRD by 7,438 euros per patient (CI 95%: 3,029 euros - 11,847 euros, p=0." | 2.71 | An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. ( Durand Zaleski, I; Gaugris, S; Hannedouche, T; Passa, P; Rodier, M; Souchet, T, 2003) |
| "Risk of stroke was increased for the first 30 days (HR 14." | 2.71 | Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. ( Dickstein, K; Lehto, M; Nieminen, MS; Snapinn, S; Swedberg, K, 2005) |
| "We examined the effect of losartan on ventricular remodeling after AMI comparatively with that of enalapril." | 2.71 | Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction. ( Hanada, H; Higuma, T; Ishizaka, H; Maeda, N; Matsunaga, T; Mori, Y; Okumura, K; Onodera, H; Osanai, T; Sasaki, S; Tamura, Y; Yoshimachi, F, 2005) |
| "When losartan was added to ACE-in treatment, there was no significant increase in A-II." | 2.69 | Safety, tolerability, and neurohormonal changes of the combination captopril plus losartan in the early postinfarction period: a pilot study. ( Bucca, V; Di Pasquale, P; Paterna, S; Scalzo, S, 1998) |
| "Losartan treatment completely prevented post-MI cardiac hypertrophy." | 1.42 | Effects of angiotensin II blockade on cardiomyocyte regeneration after myocardial infarction in rats. ( Forsten, H; Harjula, A; Immonen, K; Kankuri, E; Kosonen, R; Laine, M; Lakkisto, P; Palojoki, E; Segersvärd, H; Tikkanen, I, 2015) |
| "Treatment with losartan for MI rats significantly attenuated upregulated AT1R but not AT2R." | 1.39 | Protection of renal impairment by angiotensin II type 1 receptor blocker in rats with post-infarction heart failure. ( Cai, M; Chen, Y; Geng, D; Mai, Z; Wang, J; Wen, Z, 2013) |
| "Treatment with losartan significantly attenuated desmin- and p16(ink4a)-positive podocytes, restored podocin mRNA expression, and decreased blood cystatin C levels." | 1.39 | Angiotensin II receptor blocker attenuates intrarenal renin-angiotensin-system and podocyte injury in rats with myocardial infarction. ( Cai, MY; Chen, YX; Geng, DF; Huang, H; Jin, DM; Mai, Z; Wang, JF; Wen, ZZ, 2013) |
| "Telmisartan is an angiotensin II receptor blocker and partial peroxisome proliferator-activated receptor gamma agonist that modulates the renin-angiotensin-aldosterone system." | 1.38 | The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action. ( Han, J; Kim, HK; Kim, N; Ko, KS; Ko, TH; Lee, SR; Lee, SY; Lim, SE; Long, le T; Nilius, B; Noh, JH; Rhee, BD; Won, du N; Youm, JB, 2012) |
| " The protein levels for MnSOD were significantly elevated by exercise training in combination with losartan treatment." | 1.36 | Exercise training combined with angiotensin II receptor blockade reduces oxidative stress after myocardial infarction in rats. ( Erikson, JM; Ji, LL; Powers, AS; Wan, W; Xu, X; Zhang, JQ; Zhao, W, 2010) |
| "Losartan treatment decreases the activation of p42/44 MAPK to the uninfarcted control level and preserves normal LZ+ MYPT1 expression." | 1.35 | Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression. ( Ararat, E; Brozovich, FV, 2009) |
| " These results indicate that effects on cardiac load by peripheral AT(1) receptor blockade or the pharmacokinetic profile of subcutaneous versus oral dosing do not contribute to the different cardiac effects of central versus systemic AT(1) receptor blockade post-MI." | 1.35 | Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction. ( Ahmad, M; Huang, BS; Leenen, FH; Tan, J, 2009) |
| "Metoprolol treatment for 2 weeks improved LV systolic function." | 1.35 | Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. ( Kerkelä, R; Kubin, AM; Leskinen, H; Pieviläinen, O; Ruskoaho, H; Serpi, R; Soini, Y; Tenhunen, O; Tolonen, AM; Vaskivuo, T, 2009) |
| "Losartan treatment and exercise training were initiated 1 week after infarction and continued for 8 weeks, either as a single intervention or combined." | 1.35 | Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats. ( Erikson, JM; Ji, L; Lao, S; Powers, AS; Wan, W; Xu, X; Zhang, JQ; Zhao, W, 2008) |
| "Because myocardial infarct is associated with overactivation of brain angiotensin II (ANG II) and vasopressin (AVP) V1a receptors we decided to determine whether AT1 and V1a receptors-mediated effects of ANG II and AVP interact in central cardiovascular control during the post-infarct state." | 1.34 | Interaction of AT1 receptors and V1a receptors-mediated effects in the central cardiovascular control during the post-infarct state. ( Cudnoch-Jedrzejewska, A; Dobruch, J; Puchalska, L; Szczepańska-Sadowska, E, 2007) |
| "Losartan-treated rats exhibited a significantly less marked reduction in vascular perfusion and a significantly lesser extent of tissue hypoxia." | 1.33 | The scar neovasculature after myocardial infarction in rats. ( Ansari, R; Kiani, MF; Postlethwaite, AE; Sun, Y; Wang, B; Weber, KT, 2005) |
| "Losartan can suppress the occurrence of EAD during reperfusion following myocardial ischemia to reduce the incidence of reperfusion arrhythmias, suggesting its protective effect against myocardial ischemic injury." | 1.33 | [Protective effects of losartan against myocardial ischemic reperfusion in intact canine]. ( Chen, YL; Huang, Z; Huo, ZC; Jia, MY; Peng, J; Wang, ZM; Yang, Y, 2005) |
| "ASA, captopril or losartan were given at a concentration of 40 mg/kg/day in drinking water." | 1.32 | Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function. ( Browne, AE; Chatterjee, K; Grossman, W; Karliner, JS; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2003) |
| "Losartan treatment (2 mg/ml in drinking water, daily) was started at 4 weeks and continued for 12 weeks." | 1.32 | Antioxidant enzyme gene expression in congestive heart failure following myocardial infarction. ( Farahmand, F; Kaur, K; Khaper, N; Li, T; Singal, PK, 2003) |
| "Losartan treatment after myocardial infarction reduced the incidence of cMI from 30." | 1.32 | Losartan inhibits myosin isoform shift after myocardial infarction in rats. ( Davidoff, AW; Elkassem, S; Saito, K; ter Keurs, HE; Zhang, ML, 2003) |
| "Cardiac remodelling associated with congestive heart failure typically involves dilatation of the ventricular cavities, cardiomyocyte hypertrophy and alterations of extracellular matrix." | 1.32 | Induction of myocardial biglycan in heart failure in rats--an extracellular matrix component targeted by AT(1) receptor antagonism. ( Ahmed, MS; Andersen G, GØ; Andersson, Y; Attramadal, H; Attramadal, T; Vinge, LE; Yndestad, A; Øie, E, 2003) |
| "Since heart failure is also associated with attenuated responses to catecholamines, we examined the effects of imidapril, an ACE inhibitor, on the beta-adrenoceptor (beta-AR) signal transduction in the failing heart." | 1.32 | Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system. ( Dhalla, NS; Ren, B; Saini, HK; Sethi, R; Shao, Q; Takeda, N, 2004) |
| "Rats treated with losartan had significantly higher levels of angiotensin II in their plasma." | 1.31 | Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. ( Browne, AE; Chatterjee, K; Chou, TM; Lee, RJ; Parmley, WW; Pulukurthy, S; Sievers, RE; Sudhir, K; Sun, Y; Zhu, B, 2000) |
| "Treatment with losartan (10 mg/kg/day) began 1 week post-MI and moderate treadmill exercise (25 m/min, 60 min/day, 5 days/week) was initiated 2 weeks post-MI." | 1.31 | Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodelling in rats. ( Apstein, CS; Eberli, FR; Jain, M; Liao, R; Ngoy, S; Whittaker, P, 2000) |
| "Co-treatment with losartan prevented all changes." | 1.31 | Unchanged cardiac angiotensin II levels accompany losartan-sensitive cardiac injury due to nitric oxide synthase inhibition. ( Boer, P; Braam, B; Gröne, H; Hohbach, J; Joles, JA; Koomans, HA; Verhagen, AM, 2000) |
| "Congestive heart failure was characterized by dyspnea, depressed hemodynamic function and presence of lung and liver congestion." | 1.31 | Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. ( Khaper, N; Singal, PK, 2001) |
| "Losartan was subsequently shown to decrease central venous pressure and wedge pressure, while cardiac output, left ventricle stroke work and stroke volume all showed improvement." | 1.31 | The haemodynamic effects of losartan after right ventricle infarct in young pigs. ( Ala-Kokko, T; Alahuhta, S; Kiviluoma, K; Ruskoaho, H; Spalding, M, 2001) |
| "Total duration of arrhythmia (seconds) after I/R injury was similar in TGR and SD rats (433 +/- 109 vs." | 1.31 | Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression. ( Crijns, HJ; de Boer, RA; Pinto, YM; Suurmeijer, AJ; van Geel, PP; van Gilst, WH; van Veldhuisen, DJ, 2002) |
| "Captopril and losartan treatments were equally efficient to attenuate these parameters in both ventricles." | 1.30 | [Activation of the cardiac angiotensin-converting enzyme after myocardial infarction and its role in ventricular remodeling]. ( Busatto, VC; de Moraes, AC; Gomes, Mda G; Milanez, Mda C; Mill, JG, 1997) |
| "enalapril); combined treatment also reduced nonmyocyte cellular proliferation but did not reach statistical significance (p = 0." | 1.30 | Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. ( Aronovitz, MJ; Konstam, MA; Patten, RD; Salomon, RN; Smith, JJ; Taylor, K; Wight, J, 1998) |
| "Pretreatment with losartan abolished the significant difference between the two groups." | 1.30 | The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure. ( Kawada, T; Miyano, H; Sato, T; Shishido, T; Sugimachi, M; Sunagawa, K; Yoshimura, R, 1998) |
| "Captopril or losartan treatment reduced the extent of LV cavity dilatation." | 1.30 | Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade. ( Kim, HS; Oh, BH; Youn, TJ, 1999) |
| "Among all treatment groups myocardial infarct size was reduced significantly below saline control only by ramiprilat (-54%) and ramiprilat + angiotensin II (-37%)." | 1.29 | The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. ( Hartman, JC, 1995) |
| "Losartan was supplemented (10 mg/kg) after 1 h of reperfusion." | 1.29 | Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. ( Hartman, JC; Hullinger, TG; Shebuski, RJ; Wall, TM, 1993) |
| "Treatment with losartan was compared to untreated controls, in rats with experimental infarction and sham-operated animals." | 1.29 | The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. ( Cicutti, N; Kolar, F; Korecky, B; Papousek, F; Rakusan, K; Sladek, T; Sladkova, J, 1996) |
| " Losartan (15 mg/kg/day) resulted in a rightward shift of the AII pressor dose-response curve by a factor of 32-40." | 1.28 | Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. ( Cleutjens, JP; Daemen, MJ; Schoemaker, RG; Smits, JF; van Krimpen, C, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 40 (18.35) | 18.2507 |
| 2000's | 137 (62.84) | 29.6817 |
| 2010's | 37 (16.97) | 24.3611 |
| 2020's | 4 (1.83) | 2.80 |
| Authors | Studies |
|---|---|
| Yoo, YG | 1 |
| Lim, MJ | 1 |
| Kim, JS | 1 |
| Jeong, HE | 1 |
| Ko, H | 1 |
| Shin, JY | 1 |
| Abbasloo, E | 1 |
| Najafipour, H | 1 |
| Vakili, A | 1 |
| Xin, LH | 1 |
| Liu, R | 1 |
| Yang, XW | 1 |
| Djerada, Z | 1 |
| Bartko, PE | 1 |
| Dal-Bianco, JP | 1 |
| Guerrero, JL | 1 |
| Beaudoin, J | 1 |
| Szymanski, C | 1 |
| Kim, DH | 2 |
| Seybolt, MM | 1 |
| Handschumacher, MD | 1 |
| Sullivan, S | 1 |
| Garcia, ML | 1 |
| Titus, JS | 1 |
| Wylie-Sears, J | 1 |
| Irvin, WS | 1 |
| Messas, E | 1 |
| Hagège, AA | 1 |
| Carpentier, A | 1 |
| Aikawa, E | 1 |
| Bischoff, J | 1 |
| Levine, RA | 1 |
| Pierard, LA | 1 |
| Magne, J | 1 |
| Leenen, FHH | 1 |
| Ahmad, M | 2 |
| Marc, Y | 1 |
| Llorens-Cortes, C | 1 |
| Kolos, I | 1 |
| Loukianov, M | 1 |
| Dupik, N | 1 |
| Boytsov, S | 1 |
| Deev, A | 1 |
| Wen, Z | 1 |
| Cai, M | 1 |
| Mai, Z | 2 |
| Chen, Y | 1 |
| Geng, D | 1 |
| Wang, J | 3 |
| Segersvärd, H | 1 |
| Lakkisto, P | 1 |
| Forsten, H | 1 |
| Immonen, K | 1 |
| Kosonen, R | 1 |
| Palojoki, E | 1 |
| Kankuri, E | 1 |
| Harjula, A | 1 |
| Laine, M | 1 |
| Tikkanen, I | 1 |
| Kim, HS | 2 |
| No, CW | 1 |
| Goo, SH | 1 |
| Cha, TJ | 1 |
| Wen, ZZ | 1 |
| Cai, MY | 1 |
| Jin, DM | 1 |
| Chen, YX | 1 |
| Huang, H | 1 |
| Geng, DF | 1 |
| Wang, JF | 1 |
| Antoniou, T | 1 |
| Camacho, X | 1 |
| Yao, Z | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Mamdani, MM | 1 |
| Sgarra, L | 1 |
| Leo, V | 1 |
| Addabbo, F | 1 |
| Iacobazzi, D | 1 |
| Carratù, MR | 1 |
| Montagnani, M | 1 |
| Potenza, MA | 1 |
| Bang, CN | 2 |
| Gerdts, E | 8 |
| Aurigemma, GP | 2 |
| Boman, K | 6 |
| de Simone, G | 3 |
| Dahlöf, B | 17 |
| Køber, L | 1 |
| Wachtell, K | 10 |
| Devereux, RB | 18 |
| Li, M | 1 |
| Zheng, C | 1 |
| Kawada, T | 2 |
| Inagaki, M | 1 |
| Uemura, K | 1 |
| Sugimachi, M | 2 |
| Chen, A | 1 |
| Chen, YM | 1 |
| Vishram, JK | 1 |
| Ibsen, H | 8 |
| Kjeldsen, SE | 11 |
| Lindholm, LH | 7 |
| Mancia, G | 1 |
| Okin, PM | 4 |
| Rothwell, PM | 1 |
| Olsen, MH | 5 |
| Roman, MJ | 1 |
| Palmieri, V | 2 |
| Nieminen, MS | 10 |
| Papademetriou, V | 3 |
| Hille, DA | 4 |
| Kelloniemi, A | 1 |
| Aro, J | 2 |
| Näpänkangas, J | 1 |
| Koivisto, E | 1 |
| Mustonen, E | 2 |
| Ruskoaho, H | 4 |
| Rysä, J | 2 |
| Wald, NJ | 2 |
| Luteijn, JM | 2 |
| Morris, JK | 2 |
| Taylor, D | 1 |
| Oppenheimer, P | 1 |
| Hass, C | 1 |
| Panda, BP | 1 |
| Khanam, R | 1 |
| Najmi, AK | 1 |
| Akhtar, M | 1 |
| Marinšek, M | 1 |
| Sinkovič, A | 1 |
| Gao, XM | 1 |
| Tsai, A | 1 |
| Al-Sharea, A | 1 |
| Su, Y | 1 |
| Moore, S | 1 |
| Han, LP | 1 |
| Kiriazis, H | 1 |
| Dart, AM | 2 |
| Murphy, AJ | 1 |
| Du, XJ | 2 |
| Maczewski, M | 1 |
| Maczewska, J | 1 |
| Duda, M | 1 |
| Choi, WG | 1 |
| Kwan, J | 1 |
| Park, KS | 1 |
| Lee, WH | 1 |
| Belonje, AM | 1 |
| Westenbrink, BD | 1 |
| Voors, AA | 1 |
| von Haehling, S | 1 |
| Ponikowski, P | 1 |
| Anker, SD | 1 |
| van Veldhuisen, DJ | 2 |
| Dickstein, K | 10 |
| Wu, ZL | 1 |
| Xu, DL | 1 |
| Deng, LH | 1 |
| Wen, YW | 1 |
| Huang, P | 1 |
| Bai, SC | 1 |
| Su, L | 1 |
| Li, L | 1 |
| Liu, RY | 1 |
| Zhao, XY | 1 |
| Zhang, JY | 1 |
| Jia, M | 1 |
| Lu, PQ | 1 |
| Chua, S | 2 |
| Chang, LT | 2 |
| Sun, CK | 2 |
| Sheu, JJ | 2 |
| Lee, FY | 1 |
| Youssef, AA | 2 |
| Yang, CH | 1 |
| Wu, CJ | 2 |
| Yip, HK | 2 |
| Verjans, JW | 1 |
| Lovhaug, D | 2 |
| Narula, N | 2 |
| Petrov, AD | 1 |
| Indrevoll, B | 1 |
| Bjurgert, E | 1 |
| Krasieva, TB | 1 |
| Petersen, LB | 1 |
| Kindberg, GM | 1 |
| Solbakken, M | 1 |
| Cuthbertson, A | 1 |
| Vannan, MA | 2 |
| Reutelingsperger, CP | 1 |
| Tromberg, BJ | 1 |
| Hofstra, L | 2 |
| Narula, J | 2 |
| van den Borne, SW | 1 |
| Isobe, S | 1 |
| Zandbergen, HR | 1 |
| Li, P | 2 |
| Petrov, A | 1 |
| Wong, ND | 1 |
| Fujimoto, S | 1 |
| Fujimoto, A | 1 |
| Smits, JF | 2 |
| Daemen, MJ | 2 |
| Blankesteijn, WM | 1 |
| Reutelingsperger, C | 1 |
| Zannad, F | 1 |
| Pitt, B | 1 |
| Ararat, E | 1 |
| Brozovich, FV | 1 |
| Olofsson, M | 1 |
| González, GE | 2 |
| Seropian, IM | 1 |
| Krieger, ML | 1 |
| Palleiro, J | 2 |
| Lopez Verrilli, MA | 1 |
| Gironacci, MM | 1 |
| Cavallero, S | 1 |
| Wilensky, L | 1 |
| Tomasi, VH | 1 |
| Gelpi, RJ | 2 |
| Morales, C | 2 |
| Tani, S | 1 |
| Nagao, K | 1 |
| Anazawa, T | 1 |
| Kawamata, H | 1 |
| Furuya, S | 1 |
| Takahashi, H | 1 |
| Iida, K | 1 |
| Matsumoto, M | 1 |
| Kumabe, N | 1 |
| Onikura, M | 1 |
| Hirayama, A | 1 |
| Huang, BS | 2 |
| Tan, J | 1 |
| Leenen, FH | 3 |
| Stålhammar, J | 1 |
| Hasvold, P | 1 |
| Bodegard, J | 1 |
| Olsson, U | 1 |
| Russell, D | 1 |
| Säkkinen, H | 1 |
| Tokola, H | 1 |
| Isopoussu, E | 1 |
| Leskinen, H | 2 |
| Rokkedal, JE | 1 |
| Serpi, R | 1 |
| Tolonen, AM | 1 |
| Tenhunen, O | 1 |
| Pieviläinen, O | 1 |
| Kubin, AM | 1 |
| Vaskivuo, T | 1 |
| Soini, Y | 1 |
| Kerkelä, R | 1 |
| Cicala, S | 1 |
| Larstorp, AC | 1 |
| Xu, X | 2 |
| Zhao, W | 2 |
| Wan, W | 2 |
| Ji, LL | 1 |
| Powers, AS | 2 |
| Erikson, JM | 2 |
| Zhang, JQ | 3 |
| Lymperopoulos, A | 1 |
| Rengo, G | 1 |
| Zincarelli, C | 1 |
| Kim, J | 1 |
| Koch, WJ | 1 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 2 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 1 |
| Remuzzi, G | 2 |
| Packham, D | 1 |
| Lewis, JB | 1 |
| Parving, HH | 2 |
| Lambers Heerspink, HJ | 1 |
| Lønnebakken, MT | 1 |
| Lund, BP | 1 |
| Ogawa, K | 1 |
| Hirooka, Y | 1 |
| Kishi, T | 1 |
| Sunagawa, K | 2 |
| Sohma, R | 1 |
| Inoue, T | 1 |
| Abe, S | 1 |
| Taguchi, I | 1 |
| Kikuchi, M | 1 |
| Toyoda, S | 1 |
| Arikawa, T | 1 |
| Hikichi, Y | 1 |
| Sanada, S | 1 |
| Asanuma, H | 1 |
| Kitakaze, M | 1 |
| Node, K | 1 |
| Parlakpinar, H | 1 |
| Ozer, MK | 1 |
| Acet, A | 1 |
| Safari, F | 1 |
| Hajizadeh, S | 1 |
| Shekarforoush, S | 1 |
| Bayat, G | 1 |
| Foadoddini, M | 1 |
| Khoshbaten, A | 1 |
| Babick, A | 1 |
| Chapman, D | 2 |
| Zieroth, S | 1 |
| Elimban, V | 2 |
| Dhalla, NS | 7 |
| Kim, HK | 1 |
| Youm, JB | 1 |
| Lee, SR | 1 |
| Lim, SE | 1 |
| Lee, SY | 1 |
| Ko, TH | 1 |
| Long, le T | 1 |
| Nilius, B | 1 |
| Won, du N | 1 |
| Noh, JH | 1 |
| Ko, KS | 1 |
| Rhee, BD | 1 |
| Kim, N | 1 |
| Han, J | 1 |
| Zhu, GQ | 1 |
| Zucker, IH | 2 |
| Wang, W | 2 |
| Kjekshus, J | 6 |
| Julius, S | 6 |
| Aurup, P | 1 |
| Edelman, J | 1 |
| Beevers, G | 4 |
| de Faire, U | 5 |
| Fyhrquist, F | 5 |
| Kristianson, K | 4 |
| Lederballe-Pedersen, O | 5 |
| Omvik, P | 5 |
| Oparil, S | 6 |
| Snapinn, S | 3 |
| Wedel, H | 4 |
| Sato, H | 1 |
| Gayet, JL | 2 |
| Fournier, A | 1 |
| Andrejak, M | 2 |
| Slama, M | 1 |
| Godefroy, O | 1 |
| Achard, JM | 1 |
| Martínez-Sellés, M | 1 |
| Chowdhary, S | 1 |
| Townend, JN | 1 |
| Hamon, M | 1 |
| Filippi-Codaccioni, E | 1 |
| El-Adawi, H | 1 |
| Deng, L | 1 |
| Tramontano, A | 1 |
| Smith, S | 1 |
| Mascareno, E | 1 |
| Ganguly, K | 1 |
| Castillo, R | 1 |
| El-Sherif, N | 1 |
| Fleming, T | 1 |
| Borer, J | 1 |
| Armstrong, PW | 1 |
| Pfeffer, M | 2 |
| Patten, RD | 2 |
| Aronovitz, MJ | 2 |
| Einstein, M | 1 |
| Lambert, M | 1 |
| Pandian, NG | 1 |
| Mendelsohn, ME | 1 |
| Konstam, MA | 2 |
| Yang, YJ | 3 |
| Tang, YD | 1 |
| Ruan, YM | 3 |
| Zhang, P | 3 |
| Zhou, YW | 3 |
| Wang, PH | 1 |
| Gao, RL | 2 |
| Chen, JL | 1 |
| Chen, ZJ | 3 |
| Nicolau, JC | 2 |
| Maia, LN | 2 |
| Vítola, J | 1 |
| Vaz, VD | 1 |
| Machado, MN | 1 |
| Godoy, MF | 1 |
| Giraldez, RR | 1 |
| Ramires, JA | 1 |
| Danchin, N | 1 |
| Ambrosi, P | 1 |
| Doggrell, SA | 1 |
| Souchet, T | 1 |
| Durand Zaleski, I | 1 |
| Hannedouche, T | 1 |
| Rodier, M | 1 |
| Gaugris, S | 1 |
| Passa, P | 1 |
| Messerli, FH | 1 |
| Chintalgattu, V | 1 |
| Nair, DM | 1 |
| Katwa, LC | 1 |
| Zhu, BQ | 2 |
| Sievers, RE | 4 |
| Browne, AE | 4 |
| Lee, RJ | 4 |
| Chatterjee, K | 4 |
| Grossman, W | 2 |
| Karliner, JS | 1 |
| Parmley, WW | 4 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Schunkert, H | 1 |
| Vítola, JV | 1 |
| Santos, M | 1 |
| Brandi, JM | 1 |
| Joaquim, MR | 1 |
| Baggi, JM | 1 |
| Cordeiro, JA | 1 |
| de Godoy, MF | 1 |
| Kim, YK | 1 |
| Mankad, S | 3 |
| Kim, SJ | 1 |
| Takagi, G | 1 |
| Tamura, T | 1 |
| Gerdes, AM | 1 |
| Bishop, SP | 1 |
| Kramer, CM | 3 |
| Sidorenko, BA | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Stetsenko, TM | 1 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Yuejin, Y | 1 |
| Pei, Z | 1 |
| Yingmao, R | 1 |
| Laifeng, S | 1 |
| Xinglin, X | 1 |
| Yongli, L | 1 |
| Yanwen, Z | 1 |
| Yi, T | 1 |
| Yishu, X | 1 |
| Zaijia, C | 1 |
| Lapointe, N | 3 |
| Pourdjabbar, A | 3 |
| Rouleau, JL | 3 |
| Umemoto, S | 1 |
| Kawahara, S | 1 |
| Hashimoto, R | 1 |
| Matsuzaki, M | 1 |
| Mill, JG | 2 |
| Milanez, Mda C | 2 |
| de Resende, MM | 1 |
| Gomes, Mda G | 2 |
| Leite, CM | 1 |
| Khaper, N | 2 |
| Kaur, K | 1 |
| Li, T | 1 |
| Farahmand, F | 1 |
| Singal, PK | 2 |
| Zhang, ML | 1 |
| Elkassem, S | 1 |
| Davidoff, AW | 1 |
| Saito, K | 1 |
| ter Keurs, HE | 1 |
| Rosário, LB | 1 |
| Rocha, I | 1 |
| Silva-Carvalho, L | 1 |
| Tiede, K | 1 |
| Stöter, K | 1 |
| Petrik, C | 1 |
| Chen, WB | 1 |
| Ungefroren, H | 1 |
| Kruse, ML | 1 |
| Stoll, M | 1 |
| Unger, T | 3 |
| Fischer, JW | 1 |
| Ahmed, MS | 2 |
| Øie, E | 2 |
| Vinge, LE | 2 |
| Yndestad, A | 3 |
| Andersen G, GØ | 1 |
| Andersson, Y | 2 |
| Attramadal, T | 2 |
| Attramadal, H | 2 |
| Guo, X | 3 |
| Lindley, TE | 1 |
| Doobay, MF | 1 |
| Sharma, RV | 1 |
| Davisson, RL | 1 |
| Møller, JE | 1 |
| Dahlström, U | 1 |
| Gøtzsche, O | 1 |
| Lahiri, A | 1 |
| Skagen, K | 1 |
| Andersen, GS | 1 |
| Egstrup, K | 1 |
| Ishiyama, Y | 1 |
| Gallagher, PE | 1 |
| Averill, DB | 1 |
| Tallant, EA | 1 |
| Brosnihan, KB | 1 |
| Ferrario, CM | 1 |
| Carey, RM | 2 |
| Øystein Andersen, G | 1 |
| Mangas, F | 1 |
| Rodríguez, M | 1 |
| Depetris Chauvin, A | 1 |
| Singh, D | 2 |
| Chopra, K | 1 |
| Reims, HM | 2 |
| Brady, WE | 3 |
| Tuxen, C | 1 |
| Fossum, E | 2 |
| Bang, LE | 1 |
| Hall, C | 1 |
| Rokkedal, J | 1 |
| Hildebrandt, P | 1 |
| Keane, WF | 1 |
| Zhang, Z | 2 |
| Shahinfar, S | 2 |
| Cooper, ME | 1 |
| Mitch, WE | 1 |
| Brenner, BM | 2 |
| Borch-Johnsen, K | 1 |
| Mogensen, CE | 1 |
| Wan, Y | 1 |
| Shah, KR | 1 |
| Ganguly, PK | 1 |
| Netticadan, T | 2 |
| Arneja, AS | 1 |
| Sethi, R | 1 |
| Shao, Q | 2 |
| Ren, B | 2 |
| Saini, HK | 2 |
| Takeda, N | 2 |
| Parker, TG | 2 |
| Nguyen, QT | 2 |
| Desjardins, JF | 2 |
| Tsoporis, JN | 2 |
| Lu, L | 1 |
| Quinn, MT | 1 |
| Sun, Y | 7 |
| Bos, R | 1 |
| Mougenot, N | 1 |
| Findji, L | 1 |
| Médiani, O | 1 |
| Vanhoutte, PM | 1 |
| Lechat, P | 1 |
| Lehto, M | 1 |
| Swedberg, K | 1 |
| Ueland, T | 2 |
| Aukrust, P | 2 |
| Otterdal, K | 1 |
| Frøland, SS | 2 |
| Gullestad, L | 2 |
| Damås, JK | 1 |
| Wang, B | 3 |
| Ansari, R | 1 |
| Postlethwaite, AE | 1 |
| Weber, KT | 3 |
| Kiani, MF | 2 |
| Bourassa, MG | 1 |
| Chen, X | 2 |
| Tian, Y | 2 |
| Lyle, PA | 3 |
| Edelman, JM | 1 |
| Snapinn, SM | 1 |
| Kowey, PR | 1 |
| Dickson, TZ | 1 |
| Epifanio, HB | 1 |
| Zornoff, LA | 2 |
| Matsubara, BB | 2 |
| de Paiva, SA | 1 |
| Inoue, RM | 1 |
| Matsubara, LS | 2 |
| Liu, YH | 1 |
| Zeng, QT | 1 |
| Chen, B | 1 |
| Yang, Y | 3 |
| Huo, ZC | 1 |
| Peng, J | 1 |
| Jia, MY | 1 |
| Huang, Z | 1 |
| Wang, ZM | 1 |
| Chen, YL | 1 |
| Gao, L | 1 |
| Schultz, HD | 1 |
| Patel, KP | 1 |
| Orn, S | 2 |
| Cleland, JG | 1 |
| Romo, M | 1 |
| Trevelyan, J | 1 |
| Needham, EW | 1 |
| Morris, A | 1 |
| Mattu, RK | 1 |
| Tang, Y | 1 |
| Ruan, Y | 1 |
| Li, Y | 1 |
| Gao, R | 1 |
| Chen, Z | 1 |
| Onodera, H | 1 |
| Matsunaga, T | 1 |
| Tamura, Y | 1 |
| Maeda, N | 1 |
| Higuma, T | 1 |
| Sasaki, S | 1 |
| Mori, Y | 1 |
| Yoshimachi, F | 1 |
| Ishizaka, H | 1 |
| Hanada, H | 1 |
| Osanai, T | 1 |
| Okumura, K | 1 |
| Tingberg, E | 1 |
| Ohlin, AK | 1 |
| Gottsäter, A | 1 |
| Ohlin, H | 1 |
| Omland, T | 1 |
| Squire, IB | 2 |
| Anis, AH | 1 |
| Sun, H | 1 |
| Singh, S | 1 |
| Woolcott, J | 1 |
| Nosyk, B | 1 |
| Brisson, M | 1 |
| Cheung, BM | 1 |
| Iwata, A | 1 |
| Miura, S | 1 |
| Imaizumi, S | 1 |
| Kiya, Y | 1 |
| Nishikawa, H | 1 |
| Zhang, B | 1 |
| Shimomura, H | 2 |
| Kumagai, K | 1 |
| Matsuo, K | 1 |
| Shirai, K | 1 |
| Saku, K | 1 |
| Cudnoch-Jedrzejewska, A | 1 |
| Dobruch, J | 1 |
| Puchalska, L | 1 |
| Szczepańska-Sadowska, E | 1 |
| Kudo, Y | 1 |
| Komuro, I | 1 |
| Akazawa, H | 1 |
| Maharsy, WM | 1 |
| Kadi, LN | 1 |
| Issa, NG | 1 |
| Bitar, KM | 1 |
| Der-Boghossian, AH | 1 |
| Abrahamian, R | 1 |
| Bikhazi, AB | 1 |
| Wang, CY | 1 |
| Gleim, GW | 1 |
| Kizer, JR | 1 |
| Scott, RC | 1 |
| Pattillo, CB | 1 |
| Prabhakarpandian, B | 1 |
| Sundaram, S | 1 |
| Victor, RG | 1 |
| Longobardi, G | 1 |
| Corbi, G | 1 |
| Cacciatore, F | 1 |
| Abete, P | 1 |
| Furgi, G | 1 |
| Vitale, DF | 1 |
| Rengo, F | 1 |
| Ferrara, N | 1 |
| Manhenke, C | 1 |
| Ng, L | 1 |
| Anand, I | 1 |
| Ji, L | 1 |
| Lao, S | 1 |
| Os, I | 1 |
| Franco, V | 1 |
| Manhem, K | 1 |
| Matsuhisa, S | 1 |
| Otani, H | 2 |
| Okazaki, T | 1 |
| Yamashita, K | 1 |
| Akita, Y | 1 |
| Sato, D | 1 |
| Moriguchi, A | 1 |
| Imamura, H | 1 |
| Iwasaka, T | 1 |
| Shimamoto, K | 1 |
| Fujita, T | 1 |
| Ito, S | 1 |
| Naritomi, H | 1 |
| Ogihara, T | 1 |
| Shimada, K | 1 |
| Tanaka, H | 1 |
| Yoshiike, N | 1 |
| Capasso, JM | 1 |
| Meggs, LG | 1 |
| Herman, MV | 1 |
| Anversa, P | 1 |
| Hartman, JC | 2 |
| Stauss, HM | 1 |
| Zhu, YC | 2 |
| Redlich, T | 1 |
| Adamiak, D | 1 |
| Mott, A | 1 |
| Kregel, KC | 1 |
| Schieffer, B | 1 |
| Wirger, A | 1 |
| Meybrunn, M | 1 |
| Seitz, S | 1 |
| Holtz, J | 1 |
| Riede, UN | 1 |
| Drexler, H | 1 |
| Richard, V | 1 |
| Ghaleh, B | 1 |
| Berdeaux, A | 1 |
| Giudicelli, JF | 2 |
| Hullinger, TG | 1 |
| Wall, TM | 1 |
| Shebuski, RJ | 1 |
| Milavetz, JJ | 1 |
| Raya, TE | 4 |
| Johnson, CS | 1 |
| Morkin, E | 2 |
| Goldman, S | 3 |
| Sladek, T | 1 |
| Sladkova, J | 1 |
| Kolar, F | 1 |
| Papousek, F | 1 |
| Cicutti, N | 1 |
| Korecky, B | 1 |
| Rakusan, K | 1 |
| Deck, CC | 1 |
| Gaballa, MA | 2 |
| Krasnikova, TL | 1 |
| Pichler, M | 1 |
| Klein, W | 1 |
| Huber, K | 1 |
| Pachinger, O | 1 |
| Dixon, IM | 3 |
| Ju, H | 2 |
| Jassal, DS | 3 |
| Peterson, DJ | 1 |
| Mento, PF | 1 |
| Maita, ME | 1 |
| Wilkes, BM | 1 |
| Diaz, RJ | 1 |
| Wilson, GJ | 1 |
| De Carvalho Frimm, C | 1 |
| Lee, YM | 1 |
| Peng, YY | 1 |
| Ding, YA | 1 |
| Yen, MH | 1 |
| Zhao, S | 1 |
| Di Pasquale, P | 3 |
| Cannizzaro, S | 2 |
| Longo, AM | 1 |
| Maringhini, G | 1 |
| Iachininoto, R | 1 |
| Paterna, S | 3 |
| Schwarz, ER | 1 |
| Montino, H | 1 |
| Fleischhauer, J | 1 |
| Klues, HG | 1 |
| vom Dahl, J | 1 |
| Hanrath, P | 1 |
| Busatto, VC | 1 |
| de Moraes, AC | 1 |
| Taylor, K | 1 |
| Smith, JJ | 1 |
| Wight, J | 1 |
| Salomon, RN | 1 |
| Cox, HS | 1 |
| Esler, MD | 1 |
| Bucca, V | 2 |
| Scalzo, S | 2 |
| Sato, T | 1 |
| Yoshimura, R | 1 |
| Shishido, T | 1 |
| Miyano, H | 1 |
| Zhang, J | 1 |
| Ramires, FJ | 1 |
| Hongo, M | 1 |
| Sentianin, EM | 1 |
| Tanaka, N | 1 |
| Mao, L | 1 |
| McKirnan, MD | 1 |
| Clark, RG | 1 |
| Won, W | 1 |
| Chien, KR | 1 |
| Ross, J | 1 |
| Hu, K | 1 |
| Gaudron, P | 1 |
| Anders, HJ | 1 |
| Weidemann, F | 1 |
| Turschner, O | 1 |
| Nahrendorf, M | 1 |
| Ertl, G | 2 |
| Thai, HM | 1 |
| Van, HT | 1 |
| Zhang, GX | 1 |
| Pu, SY | 1 |
| Yang, YZ | 1 |
| Shen, XD | 1 |
| Peng, TQ | 1 |
| Chen, HZ | 1 |
| Zhang, W | 1 |
| Giubilato, A | 1 |
| Ruzicka, M | 1 |
| Yuan, B | 1 |
| Lynch, JJ | 1 |
| Stump, GL | 1 |
| Wallace, AA | 1 |
| Painter, CA | 1 |
| Thomas, JM | 1 |
| Kusma, SE | 1 |
| Gould, RJ | 1 |
| Youn, TJ | 1 |
| Oh, BH | 1 |
| Richer, C | 1 |
| Gervais, M | 1 |
| Fornes, P | 1 |
| Zhu, B | 2 |
| Pulukurthy, S | 1 |
| Sudhir, K | 1 |
| Chou, TM | 1 |
| Jain, M | 1 |
| Liao, R | 1 |
| Ngoy, S | 1 |
| Whittaker, P | 1 |
| Apstein, CS | 1 |
| Eberli, FR | 1 |
| Spinar, J | 2 |
| Vitovec, J | 2 |
| Spinarova, L | 2 |
| Pluhacek, L | 2 |
| Fischerova, B | 2 |
| Toman, J | 2 |
| Siragy, HM | 1 |
| Verhagen, AM | 1 |
| Hohbach, J | 1 |
| Joles, JA | 1 |
| Braam, B | 1 |
| Boer, P | 1 |
| Koomans, HA | 1 |
| Gröne, H | 1 |
| Sato, M | 1 |
| Engelman, RM | 1 |
| Maulik, N | 1 |
| Rousou, JA | 1 |
| Flack, JE | 1 |
| Deaton, DW | 1 |
| Das, DK | 1 |
| Hao, J | 1 |
| Jones, SC | 1 |
| Paiva, SA | 1 |
| Spadaro, J | 1 |
| Staufenberger, S | 1 |
| Jacobs, M | 1 |
| Brandstätter, K | 1 |
| Hafner, M | 1 |
| Regitz-Zagrosek, V | 1 |
| Schorb, W | 1 |
| Soejima, H | 1 |
| Ogawa, H | 1 |
| Suefuji, H | 1 |
| Kaikita, K | 1 |
| Takazoe, K | 1 |
| Miyamoto, S | 1 |
| Kajiwara, I | 1 |
| Sakamoto, T | 1 |
| Yoshimura, M | 1 |
| Nakamura, S | 1 |
| Lee, S | 1 |
| Yoo, SE | 1 |
| Sandberg, K | 1 |
| d'Amato, TA | 1 |
| Reichek, N | 1 |
| McGregor, WE | 1 |
| Lin, J | 1 |
| Rogers, WJ | 1 |
| McMurray, JJ | 1 |
| Spalding, M | 1 |
| Ala-Kokko, T | 1 |
| Kiviluoma, K | 1 |
| Alahuhta, S | 1 |
| Ouali, N | 1 |
| Daniëls, MC | 1 |
| Keller, RS | 1 |
| de Tombe, PP | 1 |
| Zhang, G | 1 |
| Shen, X | 1 |
| Pu, S | 1 |
| Pan, W | 1 |
| Chen, H | 1 |
| Zhu, YZ | 1 |
| Li, J | 2 |
| Schäfer, H | 1 |
| Schmidt, W | 1 |
| Yao, T | 1 |
| Loennechen, JP | 1 |
| Wisløff, U | 1 |
| Falck, G | 1 |
| Ellingsen, O | 1 |
| de Boer, RA | 1 |
| van Geel, PP | 1 |
| Pinto, YM | 1 |
| Suurmeijer, AJ | 1 |
| Crijns, HJ | 1 |
| van Gilst, WH | 1 |
| Xu, Y | 1 |
| Menon, V | 1 |
| Jugdutt, BI | 1 |
| Hillman, RT | 1 |
| Chair, K | 1 |
| Glantz, SA | 1 |
| Xiu, JC | 1 |
| Wu, P | 1 |
| Xu, JP | 1 |
| Guo, Z | 1 |
| Lai, W | 1 |
| Zhang, Y | 1 |
| Li, S | 1 |
| Liu, Y | 1 |
| Scheen, AJ | 1 |
| van Krimpen, C | 1 |
| Schoemaker, RG | 1 |
| Cleutjens, JP | 1 |
| Fonken, SJ | 1 |
| Lee, RW | 1 |
| Daugherty, S | 1 |
| Wong, PC | 1 |
| Timmermans, PB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis[NCT00805311] | Phase 4 | 400 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Due to the clear advantage of carotid endarterectomy) | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After ST-elevation Myocardial Infarction[NCT03516903] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2018-04-17 | Terminated (stopped due to Due to the COVID-19 pandemic. With a second wave just beginning, and considering that we are testing an immunosuppressant in patients with high risk for COVID-19 complications, we would not be able to re-start recruitment safely in the near future.) | ||
| The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019[NCT04338009] | 152 participants (Actual) | Interventional | 2020-03-31 | Completed | |||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124] | Phase 3 | 291 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 10 |
| Continuation Arm | 11 |
"The Area Under the Curve of the modified SOFA (AUC SOFA) from daily measurements, weighted to account for the shorter observation period among patients who die in-hospital.~How to interpret the AUC SOFA?: a higher area indicates more severe disease and/or longer hospitalization.The range is 0.1 to 377.3." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | units on a scale (SOFA x days) (Median) |
|---|---|
| Discontinuation Arm | 7 |
| Continuation Arm | 12 |
"The primary endpoint of the trial will be a global rank based on patient outcomes according to four factors: (1) time to death, (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), (3) the number of days supported by renal replacement therapy or pressor/inotropic therapy, and (4) a modified sequential Organ Failure Assessment (SOFA) score. The modified SOFA score will include the cardiac, respiratory, renal and coagulation domains of the SOFA score.~How to interpret the rank?: patients are ranked from worst to best outcomes, such that patients with bad outcomes are ranked at the top and patients who have the best outcomes are ranked at the bottom." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | score on a scale (range 1 to 152) (Median) |
|---|---|
| Discontinuation Arm | 81 |
| Continuation Arm | 73 |
Hypotension Requiring Vasopressors, inotropes or mechanical hemodynamic support (ventricular assist device or intra-aortic balloon pump). (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 8 |
| Continuation Arm | 9 |
Need to be transferred to an intensive care unit or to supported by a breathing machine (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 14 |
| Continuation Arm | 16 |
This outcome measurement looked at the median length of hospitalization. (NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 5 |
| Continuation Arm | 6 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 15 |
| Continuation Arm | 13 |
14 reviews available for losartan and Myocardial Infarction
| Article | Year |
|---|---|
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
[Acute myocardial infarction].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Tria | 2002 |
[The best of clinical pharmacology in 2002].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; H | 2003 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
[Blocker of angiotensin-1 receptor antagonist losartan. Part III. Experience in therapy for chronic heart failure and after acute myocardial infarction].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Heart Failure; Humans; Los | 2003 |
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Fai | 2003 |
Therapeutic potential of angiotensin receptor blockers in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2006 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2007 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2007 |
Pathophysiology of target-organ disease: does angiotensin II remain the key?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2007 |
[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1996 |
[Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1996 |
Prospective trials of angiotensin receptor blockers: beyond blood pressure control.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Los | 2000 |
Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2001 |
44 trials available for losartan and Myocardial Infarction
| Article | Year |
|---|---|
Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Carotid Stenosis; Combined Modality Therapy; Endartere | 2015 |
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; De | 2014 |
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu | 2015 |
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2015 |
Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial.
Topics: Aged; Biomarkers; Cardiovascular Agents; Fibrinolysis; Heart Failure; Humans; Losartan; Middle Aged; | 2016 |
Effects of early losartan therapy on ventricular late potentials in acute myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans | 2008 |
Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Exercise; Fe | 2009 |
Effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction: a possible mechanism of prevention of cardiac events by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk myocardial
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Cardiotonic Agents; | 2009 |
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.
Topics: Aged; Blood Pressure; Cardiovascular System; Echocardiography; Endocardium; Female; Follow-Up Studie | 2010 |
Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; An | 2010 |
In-treatment stroke volume predicts cardiovascular risk in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Follo | 2011 |
Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Body Mass Index; Body Weight; Doub | 2013 |
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Endpoint Determi | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
ACE inhibitors or AT-1 antagonists - which is OPTIMAAL after acute myocardial infarction?
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double- | 2003 |
An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France.
Topics: Antihypertensive Agents; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Dia | 2003 |
[Reduction of cardiovascular events with lorsartan? The LIFE Study].
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cerebral Infarction; Doub | 2003 |
Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Enalapril; Fe | 2003 |
Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; Echo | 2004 |
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Antihypertensive Agents; Atenolol; Female; Humans; Hypert | 2004 |
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
Topics: Aged; Anti-Infective Agents; Atenolol; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hyp | 2004 |
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cardiovasc | 2004 |
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; | 2004 |
Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; Captopr | 2005 |
Soluble CD40 ligand in acute and chronic heart failure.
Topics: Acute Disease; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2005 |
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; | 2004 |
Losartan and end-organ protection--lessons from the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Ty | 2005 |
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Death, Sudden, Cardiac; Female; Follo | 2005 |
Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery D | 2005 |
Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Humans; | 2005 |
Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2006 |
Do valsartan and losartan have the same effects in the treatment of coronary artery disease?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Case-Control Studies; Coronary Angiography; Coronary | 2007 |
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Compli | 2007 |
Effect of losartan in treatment of exercise-induced myocardial ischemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Coronary Artery Disease; Cross-Over Studies | 2007 |
Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2007 |
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Female; | 2008 |
Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Biphenyl Compounds; Blott | 1996 |
Captopril plus losartan in early post-infarction. Neurohormonal effects: a pilot study.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination | 1997 |
Safety, tolerability, and neurohormonal changes of the combination captopril plus losartan in the early postinfarction period: a pilot study.
Topics: Acute Disease; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Humans; Losartan; Male; | 1998 |
Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihyperten | 1999 |
A comparison of intervention with losartan or captopril in acute myocardial infarction.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Met | 2000 |
First dose hypotension after angiotensin converting enzyme inhibitor captopril and angiotensin II blocker losartan in patients with acute myocardial infarction.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Captopril; | 2000 |
Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiote
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; | 2001 |
Comparison of effects of losartan versus enalapril on fibrinolysis and coagulation in patients with acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Coagulation Factors; Double-Blind Met | 2001 |
160 other studies available for losartan and Myocardial Infarction
| Article | Year |
|---|---|
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2023 |
Chronic treatment with apelin, losartan and their combination reduces myocardial infarct size and improves cardiac mechanical function.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Apelin; Drug Therapy, Comb | 2020 |
Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway.
Topics: Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Disease Models, Animal; | 2020 |
Comparison of the effects of losartan, captopril, angiotensin II type 2 receptor agonist compound 21, and MAS receptor agonist AVE 0991 on myocardial ischemia-reperfusion necrosis in rats.
Topics: Animals; Captopril; Imidazoles; Losartan; Myocardial Infarction; Myocardial Reperfusion Injury; Rats | 2021 |
Effect of Losartan on Mitral Valve Changes After Myocardial Infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography, Three-Di | 2017 |
New Pharmacological Target to Treat Ischemic Mitral Regurgitation: Thinking Outside the Box.
Topics: Humans; Losartan; Mitral Valve; Mitral Valve Insufficiency; Myocardial Infarction; Myocardial Ischem | 2017 |
Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin III; Animals; Brain; Dise | 2019 |
Protection of renal impairment by angiotensin II type 1 receptor blocker in rats with post-infarction heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Heart Failure; Kidney; Kidney Function Tests; Losa | 2013 |
Effects of angiotensin II blockade on cardiomyocyte regeneration after myocardial infarction in rats.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Antimetabolites; Apoptosis; Body Weight; Bromodeox | 2015 |
An Angiotensin receptor blocker prevents arrhythmogenic left atrial remodeling in a rat post myocardial infarction induced heart failure model.
Topics: Angiotensin Receptor Antagonists; Animals; Atrial Fibrillation; Atrial Remodeling; Disease Models, A | 2013 |
Angiotensin II receptor blocker attenuates intrarenal renin-angiotensin-system and podocyte injury in rats with myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Cellular Senescence; Gene Expression; Insulin-Like Growth | 2013 |
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compo | 2013 |
Intermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: role of BK2 receptors.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Bradykinin; Cardiotonic Agents; Heart | 2014 |
Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cholinesterase Inhibitors; Chronic Disease; Diseas | 2014 |
Donepezil, a potential therapeutic agent for heart failure.
Topics: Animals; Heart Failure; Indans; Losartan; Myocardial Infarction; Piperidines | 2015 |
TSC-22 up-regulates collagen 3a1 gene expression in the rat heart.
Topics: Animals; Antihypertensive Agents; Cells, Cultured; Collagen Type III; Female; Gene Expression; Gene | 2015 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort St | 2016 |
Histamine H3 Receptor Agonist Imetit Attenuated Isoproterenol Induced Renin Angiotensin System and Sympathetic Nervous System Overactivity in Myocardial Infarction of Rats.
Topics: Angiotensin II; Animals; Antioxidants; Cardiotonic Agents; Histamine Agonists; Histamine H3 Antagoni | 2016 |
Starting the polypill: the use of a single age cut-off in males and females.
Topics: Adult; Age Factors; Aged; Cardiovascular Agents; Drug Combinations; Female; Humans; Hydrochlorothiaz | 2017 |
Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anima | 2017 |
Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Atorvastatin; Drug Thera | 2008 |
Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; | 2009 |
[Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats].
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Losartan; M | 2008 |
Effects of combination therapy with perindopril and losartan on left ventricular remodelling in patients with myocardial infarction.
Topics: Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Losartan; Male; Middle Aged; Myo | 2009 |
Time courses of subcellular signal transduction and cellular apoptosis in remote viable myocardium of rat left ventricles following acute myocardial infarction: role of pharmacomodulation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Gene Expression Regulation; Heart Ventr | 2009 |
Noninvasive imaging of angiotensin receptors after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Binding Sites; Biomarkers; Disease | 2008 |
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri | 2009 |
Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; C | 2009 |
Effect of early versus late AT(1) receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Colla | 2009 |
Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Echocardiography; Injections | 2009 |
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; F | 2010 |
Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis Regulatory Proteins; Cel | 2010 |
Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction.
Topics: Animals; Antihypertensive Agents; Apoptosis; Cell Count; Cell Proliferation; Heart Ventricles; Inter | 2009 |
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Follow-Up S | 2011 |
Exercise training combined with angiotensin II receptor blockade reduces oxidative stress after myocardial infarction in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Catalase; Combined Modality Therapy; Disease Model | 2010 |
Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels.
Topics: Adrenal Glands; Aldosterone; Animals; Arrestins; beta-Arrestin 1; beta-Arrestins; Cell Line; Disease | 2011 |
Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure.
Topics: Angiotensin II; Animals; Body Weight; Brain; Brain Stem; Electrocardiography; Heart; Heart Failure; | 2011 |
Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiotonic Agents; Coronary Circulation; Disease Models, | 2012 |
Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries; Blood | 2011 |
Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Heart; Heart Rate | 2012 |
Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium-Binding Proteins; Cardiomegaly; Catecholam | 2012 |
The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Calc | 2012 |
Central AT1 receptors are involved in the enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure.
Topics: Anesthetics, Local; Angiotensin II; Animals; Anti-Arrhythmia Agents; Bradykinin; Capsaicin; Heart Fa | 2002 |
The OPTIMAAL trial: losartan or captopril after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Humans; Losartan; Myo | 2002 |
The OPTIMMAL trial: losartan or captopril after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Humans; Losartan; Myo | 2002 |
The OPTIMMAL trial: losartan or captopril after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Humans; Losartan; Myo | 2002 |
The OPTIMMAL trial: losartan or captopril after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Humans; Losartan; Myo | 2002 |
The OPTIMMAL trial: losartan or captopril after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Humans; Losartan; Myo | 2002 |
The functional role of the JAK-STAT pathway in post-infarction remodeling.
Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Apoptosis; DNA-Binding Proteins; Janus Kinase 1; Ja | 2003 |
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Ca | 2003 |
Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Collagen; Enala | 2003 |
Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats.
Topics: Animals; Carbazoles; Carvedilol; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; He | 2003 |
ST-segment resolution and late (6-month) left ventricular remodeling after acute myocardial infarction.
Topics: Aged; Antihypertensive Agents; Coronary Circulation; Electrocardiography; Enalapril; Female; Humans; | 2003 |
[Suboptimal results of Optimaal: treatment with ACE inhibitors remains the preferred therapy in patients with left ventricular dysfunction after acute myocardial infarct]].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause of Death; Female; Humans; Length of Stay; | 2002 |
The LIFE study: the straw that should break the camel's back.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; My | 2003 |
Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Fibroblasts; Imidazoles; Losartan; Male; | 2003 |
Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2003 |
What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause of Deat | 2003 |
Adding angiotensin II type 1 receptor blockade to angiotensin-converting enzyme inhibition limits myocyte remodeling after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Female; Losarta | 2003 |
Comparison of the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling after acute myocardial infarction in the rat.
Topics: Animals; Antihypertensive Agents; Drug Synergism; Enalapril; Female; Losartan; Myocardial Infarction | 2002 |
The OPTIMAAL study, not so optimal: the lessons of LIFE, RENAAL and IDNT.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; | 2003 |
Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats.
Topics: Animals; Cicatrix; Collagen; Hydralazine; Losartan; Male; Myocardial Infarction; Myocardium; Organ S | 2003 |
Antioxidant enzyme gene expression in congestive heart failure following myocardial infarction.
Topics: Animals; Antihypertensive Agents; Antioxidants; Catalase; Enzymes; Gene Expression; Glutathione Pero | 2003 |
Losartan inhibits myosin isoform shift after myocardial infarction in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Body Weight; Heart Failure; Hemo | 2003 |
Effect of losartan microinjections into the NTS on the cardiovascular components of chemically evoked reflexes in a rabbit model of acute heart ischemia.
Topics: Acute Disease; Animals; Capsaicin; Chemoreceptor Cells; Disease Models, Animal; Female; Losartan; Ma | 2003 |
Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro.
Topics: Angiotensin II; Animals; Animals, Newborn; Anti-Arrhythmia Agents; Autocrine Communication; Biglycan | 2003 |
Induction of myocardial biglycan in heart failure in rats--an extracellular matrix component targeted by AT(1) receptor antagonism.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biglycan; Extracellular M | 2003 |
Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blotting, Northern; Blotting, Western; Calci | 2003 |
Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure.
Topics: Adenoviridae; Animals; Antihypertensive Agents; Brain; Genetic Vectors; Heart Failure; Humans; Injec | 2004 |
[New options against undertreatment].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Top | 2003 |
Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2004 |
Angiotensin type-1 receptor blockade increases ACE 2 expression in the heart.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Ca | 2004 |
Connective tissue growth factor--a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats.
Topics: Administration, Oral; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhyth | 2004 |
[Effects of the early administration of losartan on ventricular remodeling in rabbits with experimental myocardial infarction].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Fibrosis; Losartan; Myoca | 2004 |
Evidence of the role of angiotensin AT(1) receptors in remote renal preconditioning of myocardium.
Topics: Angiotensin II; Animals; Blood Pressure; Body Temperature; Coronary Vessels; Disease Models, Animal; | 2004 |
Changes in skeletal muscle SR Ca2+ pump in congestive heart failure due to myocardial infarction are prevented by angiotensin II blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2004 |
Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan.
Topics: Adenosine Triphosphatases; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agent | 2004 |
Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
Topics: Adenylyl Cyclases; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Enalap | 2004 |
Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Blood Pressure; | 2005 |
Oxidative stress in the infarcted heart: role of de novo angiotensin II production.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Heart Ventricles; Lo | 2004 |
Sarcoplasmic reticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment.
Topics: Animals; Antihypertensive Agents; Calcium; Calcium-Transporting ATPases; Cardiomegaly; Enalapril; Ge | 2005 |
Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist.
Topics: Adrenergic beta-Agonists; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Anim | 2005 |
The scar neovasculature after myocardial infarction in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cicatrix; Losartan; Male; Myocardial Infarction; N | 2005 |
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
[Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Collagen Type I; Collagenases; Doxycycline; Drug S | 2005 |
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2005 |
[Myocardial remodeling after experimental acute myocardial infarction in rats. Effect of renin-angiotensin-aldosterone blockade].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease | 2005 |
[Comparative study of effects of fluvastatin and losartan on left ventricular remodeling in rat myocardial infarction].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Drug Therapy, Combinatio | 2005 |
[Protective effects of losartan against myocardial ischemic reperfusion in intact canine].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dogs; Electrophysiology; Female; Losartan; Male; M | 2005 |
Augmented input from cardiac sympathetic afferents inhibits baroreflex in rats with heart failure.
Topics: Animals; Antihypertensive Agents; Arteries; Baroreflex; Capsaicin; Cardiac Output, Low; Chronic Dise | 2005 |
[Utilizing progress in modern antihypertensive therapy. Treating hypertension effectively from the beginning].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as | 2005 |
[Comparison of doxycycline, losartan, and their combination in the prevention of post-infarction remodeling in rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Doxycycline; Female; Losartan; Myocardial Infarcti | 2005 |
[Comparative effects of carvedilol, losartan and their combination in preventing left ventricular remodeling after acute myocardial infarction in rats].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Carbazoles; Carvedilo | 2001 |
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; C | 2005 |
Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chemokine CCL2; Creatinine; Female; Heart | 2005 |
Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: reduced ventricular arrhythmias and improved survival.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pressure; Gene Express | 2005 |
A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cohort Studies | 2006 |
Interaction of AT1 receptors and V1a receptors-mediated effects in the central cardiovascular control during the post-infarct state.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antidiuretic Hormone Receptor Antagonists; Arginin | 2007 |
Cross-talk related to insulin and angiotensin II binding on myocardial remodelling in diabetic rat hearts.
Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Expe | 2007 |
Losartan preserves integrity of cardiac gap junctions and PGC-1 alpha gene expression and prevents cellular apoptosis in remote area of left ventricular myocardium following acute myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Down-Regulation; Gap Junctions; Gene Ex | 2007 |
Microvascular transport model predicts oxygenation changes in the infarcted heart after treatment.
Topics: Angiogenesis Inducing Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Computer Simulation; | 2007 |
Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Collagen; Combined Modality Therapy; Disease Model | 2008 |
Angiotensin II type 1 receptor blocker preserves tolerance to ischemia-reperfusion injury in Dahl salt-sensitive rat heart.
Topics: Aldehydes; Amidines; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzylamines; D | 2008 |
Both enalapril and losartan attenuate sarcolemmal Na+-K+-ATPase remodeling in failing rat heart due to myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease | 2008 |
Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Femal | 2008 |
Efficacy of angiotensin-converting enzyme inhibition and AT1 receptor blockade on cardiac pump performance after myocardial infarction in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 1994 |
The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
Topics: Adrenergic beta-Antagonists; Amino Acid Oxidoreductases; Angiotensin II; Angiotensin Receptor Antago | 1995 |
Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inh | 1994 |
Angiotensin II receptor binding following myocardial infarction in the rat.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Autoradiography; Biphenyl Compounds; Coll | 1994 |
Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Coronary Circulation; | 1994 |
Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.
Topics: Anesthesia; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Coronar | 1993 |
Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressur | 1993 |
Survival after myocardial infarction in rats: captopril versus losartan.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1996 |
The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Capill | 1996 |
Relative contribution of angiotensin II, bradykinin, and prostaglandins to the renal effects of converting enzyme inhibition in rats after chronic myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Bradykinin; Bradykinin Recept | 1996 |
Renal hemodynamics in rats with myocardial infarction: selective antagonism of angiotensin receptor subtypes.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Hemodynamics; Imidazoles; Losartan; M | 1996 |
Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Coronary Circul | 1997 |
Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1997 |
Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats.
Topics: Acute Disease; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Ar | 1997 |
Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biomarkers; Blot | 1997 |
Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart.
Topics: Angiotensin Receptor Antagonists; Animals; Enalaprilat; Hemodynamics; Imidazoles; Losartan; Male; My | 1997 |
[Activation of the cardiac angiotensin-converting enzyme after myocardial infarction and its role in ventricular remodeling].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopri | 1997 |
Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1998 |
Depression of efferent parasympathetic control of heart rate in rats with myocardial infarction: effect of losartan.
Topics: Acetylcholine; Animals; Anti-Arrhythmia Agents; Blood Pressure; Bradycardia; Heart Rate; Losartan; M | 1998 |
The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Brain; Captopril; Evalua | 1998 |
Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart.
Topics: Angiotensin II; Animals; Collagen; Fibrosis; Losartan; Male; Myocardial Infarction; Myocardium; Pept | 1998 |
Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Blood Flow Veloci | 1998 |
Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Angiotensin I; Angiotensin Receptor Antagonists; | 1998 |
Effects of AT1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility.
Topics: Angiotensin Receptor Antagonists; Animals; Aorta; Blood Pressure; Elasticity; Heart; Heart Rate; Hem | 1999 |
Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Method; H | 1999 |
Effect of losartan and captopril on expression of cardiac angiotensin II AT1 receptor mRNA in rats following myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Gene | 1997 |
Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Baroreflex; Bloo | 1999 |
Blockade of AT(1) receptors and Na(+)/H(+) exchanger and LV dysfunction after myocardial infarction in rats.
Topics: Amiloride; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Blood Volume; Drug Combination | 1999 |
EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
Topics: Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhyt | 1999 |
Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Echo | 1999 |
Combined selective angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1999 |
Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2000 |
Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodelling in rats.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Losartan; M | 2000 |
Unchanged cardiac angiotensin II levels accompany losartan-sensitive cardiac injury due to nitric oxide synthase inhibition.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cardiomegaly; Dose-Respon | 2000 |
Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensins; Animals; Apoptosis; Bra | 2000 |
Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro.
Topics: Active Transport, Cell Nucleus; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihyper | 2000 |
Effects of losartan on ventricular remodeling in experimental infarction in rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Hydroxyproline; Losartan; Ma | 2000 |
Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats.
Topics: Angiotensin Receptor Antagonists; Animals; Catalase; Glutathione Peroxidase; Heart Failure; Lipid Pe | 2001 |
Angiotensin II type 1 receptor regulation and differential trophic effects on rat cardiac myofibroblasts after acute myocardial infarction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Becaplermin; Binding, Competitive; Cell D | 2001 |
Combined angiotensin converting enzyme inhibition and angiotensin AT(1) receptor blockade up-regulates myocardial AT(2) receptors in remodeled myocardium post-infarction.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; An | 2001 |
Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; | 2001 |
The haemodynamic effects of losartan after right ventricle infarct in young pigs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Female; Heart Ventricles; | 2001 |
[Complications in kidney transplantation].
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Graft Rejection; Humans; H | 2001 |
Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Calcium; Female; Heart Failure; | 2001 |
Comparative effects of losartan and captopril on ventricular remodeling and function after myocardial infarction in the rat.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Hear | 1998 |
Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Coronary Circulation; Hemodynami | 2000 |
Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Disease Mode | 2001 |
Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure.
Topics: Angiotensins; Animals; Anti-Arrhythmia Agents; Calcium Signaling; Cardiomegaly; Cell Separation; Cel | 2002 |
Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression.
Topics: Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Anti-Arrhythmia Agents; Ar | 2002 |
Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-recep
Topics: Angiotensin Receptor Antagonists; Animals; Blood Volume; Calcium Channels; Cardiotonic Agents; Cycli | 2000 |
The renin-angiotensin system does not contribute to the endothelial dysfunction and increased infarct size in rats exposed to second hand smoke.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Electrocardiography; Endothe | 2002 |
Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; | 2002 |
[Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan].
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Endpoint Determination; Female; H | 2002 |
Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardi | 1992 |
Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure.
Topics: Administration, Oral; Angiotensin II; Animals; Body Weight; Captopril; Cardiac Output, Low; Complian | 1991 |